Author: Editor

Dr. Kohei Shitara is a Chief of Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa in Japan. In this interview, he speaks about the ASCO GI 2022 Abstract – Exploratory analysis of the impact of prior immune checkpoint inhibitor (ICI) on trastuzumab deruxtecan (T-DXd; DS-8201) clinical outcomes and biomarkers (BM) in DESTINY-Gastric01 (DG-01), a randomized, phase 2, multicenter, open-label study in patients (pts) with HER2+ advanced gastric or gastroesophageal junction adenocarcinoma.Context:T-DXd is an antibody-drug combination that targets HER2. T-DXd showed clinically meaningful improvements in objective response rate (ORR) and overall survival (OS) compared to chemotherapy in the primary…

Dr. Kohei Shitara is a Chief of Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa in Japan. In this interview, he speaks about the ASCO GI 2022 Abstract – Exploratory analysis of the impact of prior immune checkpoint inhibitor (ICI) on trastuzumab deruxtecan (T-DXd; DS-8201) clinical outcomes and biomarkers (BM) in DESTINY-Gastric01 (DG-01), a randomized, phase 2, multicenter, open-label study in patients (pts) with HER2+ advanced gastric or gastroesophageal junction adenocarcinoma.Context:T-DXd is an antibody-drug combination that targets HER2. T-DXd showed clinically meaningful improvements in objective response rate (ORR) and overall survival (OS) compared to chemotherapy in the primary…

Richard Francis Dunne, MD, Assistant Professor – Department of Medicine, Hematology/Oncology (SMD) at the University of Rochester Medical Center. In this interview, he speaks about the ASCO GI 2022 Abstract Induction FOLFOX prior to CROSS chemoradiotherapy and surgery in patients with locally-advanced esophageal and gastroesophageal junction cancer: A phase II study.Origins:In the CROSS study, it was discovered that neoadjuvant chemoradiotherapy (CRT) is given before surgery to patients with esophageal (E) and gastroesophageal junction (GEJ) malignancies improved survival. However, 10-year data did not suggest that minimizing isolated distant metastases was beneficial. Prior to CRT, adding full-dose induction chemotherapy (CT) could give…

Richard Francis Dunne, MD, Assistant Professor – Department of Medicine, Hematology/Oncology (SMD) at the University of Rochester Medical Center. In this interview, he speaks about the ASCO GI 2022 Abstract Induction FOLFOX prior to CROSS chemoradiotherapy and surgery in patients with locally-advanced esophageal and gastroesophageal junction cancer: A phase II study.Origins:In the CROSS study, it was discovered that neoadjuvant chemoradiotherapy (CRT) is given before surgery to patients with esophageal (E) and gastroesophageal junction (GEJ) malignancies improved survival. However, 10-year data did not suggest that minimizing isolated distant metastases was beneficial. Prior to CRT, adding full-dose induction chemotherapy (CT) could give…

Dr. Timothy Schmidt from the Carbone Cancer Center, and the University of Wisconsin, is a faculty member of the Division of Hematology, Medical Oncology, and Palliative Care within the Department of Medicine. He is a member of the American Society of Hematology, the American Society of Clinical Oncology, and the International Myeloma Society. Dr. Schmidt also serves as a peer reviewer for clinical hematology journals and is involved in medical education for trainees, medical professionals, and patient outreach organizations. In this video Dr. Schmidt speaks about the ASH 2021 Abstract – 467 Impact of Chromosome 1 Abnormalities Among Patients with…

Dr. Timothy Schmidt from the Carbone Cancer Center, and the University of Wisconsin, is a faculty member of the Division of Hematology, Medical Oncology, and Palliative Care within the Department of Medicine. He is a member of the American Society of Hematology, the American Society of Clinical Oncology, and the International Myeloma Society. Dr. Schmidt also serves as a peer reviewer for clinical hematology journals and is involved in medical education for trainees, medical professionals, and patient outreach organizations. In this video Dr. Schmidt speaks about the ASH 2021 Abstract – 467 Impact of Chromosome 1 Abnormalities Among Patients with…

Daniel Herranz, PharmD, Ph.D., Assistant Professor in the Department of Pharmacology at the Robert Wood Johnson Medical School & Resident Member at Rutgers Cancer Institute of New Jersey speaks about the ASH 2021 Abstract 2221 Sirt1 Is a Novel Therapeutic Target in T-ALL.Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper153950.htmlT-cell Acute Lymphoblastic Leukemia (T-ALL) is leukemia that affects both children and adults. Despite this, 20 percent to 50 percent of individuals develop initial resistance or relapse after treatment and eventually succumb to their illness. Because more than 60% of T-ALL individuals have to activate mutations in the NOTCH1 gene, abnormal NOTCH1 signaling plays a key…

Daniel Herranz, PharmD, Ph.D., Assistant Professor in the Department of Pharmacology at the Robert Wood Johnson Medical School & Resident Member at Rutgers Cancer Institute of New Jersey speaks about the ASH 2021 Abstract 2221 Sirt1 Is a Novel Therapeutic Target in T-ALL.Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper153950.htmlT-cell Acute Lymphoblastic Leukemia (T-ALL) is leukemia that affects both children and adults. Despite this, 20 percent to 50 percent of individuals develop initial resistance or relapse after treatment and eventually succumb to their illness. Because more than 60% of T-ALL individuals have to activate mutations in the NOTCH1 gene, abnormal NOTCH1 signaling plays a key…

The discussion was on Tuesday, December 7, 2021Optimizing Immunotherapy in Triple-Negative Breast Cancer: Novel Predictive Biomarkers and Blood-Basted Efficacy MonitoringSpeaker -Hope Rugo, MDSpeaks about Challenges and Opportunities for Optimizing Immunotherapies for TNBC

The discussion was on Tuesday, December 7, 2021Optimizing Immunotherapy in Triple-Negative Breast Cancer: Novel Predictive Biomarkers and Blood-Basted Efficacy MonitoringSpeaker -Adam Brufsky, MD, Ph.D.Speaks about Navigating Treatment Decision Points in Management of TNBC: Interactive Case Studies

The discussion was on Tuesday, December 7, 2021Optimizing Immunotherapy in Triple-Negative Breast Cancer: Novel Predictive Biomarkers and Blood-Basted Efficacy MonitoringSpeakers -Adam Brufsky, MD, Ph.D. – Interactive Case StudiesSpeaks about Navigating Treatment Decision Points in Management of TNBC: Interactive Case StudiesGiampaolo Bianchini, MDSpeaks about Harnessing the TNBC Microenvironment to Integrate Novel Predictive BiomarkersHope Rugo, MDSpeaks about Callenges and Oppotrunites for Optimizing Immunotherapies for TNBC

The discussion was on Tuesday, December 7, 2021Optimizing Immunotherapy in Triple-Negative Breast Cancer: Novel Predictive Biomarkers and Blood-Basted Efficacy MonitoringSpeakers -Adam Brufsky, MD, Ph.D. – Interactive Case StudiesSpeaks about Navigating Treatment Decision Points in Management of TNBC: Interactive Case StudiesGiampaolo Bianchini, MDSpeaks about Harnessing the TNBC Microenvironment to Integrate Novel Predictive BiomarkersHope Rugo, MDSpeaks about Callenges and Oppotrunites for Optimizing Immunotherapies for TNBC

The discussion was on Tuesday, December 7, 2021Optimizing Immunotherapy in Triple-Negative Breast Cancer: Novel Predictive Biomarkers and Blood-Basted Efficacy MonitoringSpeaker -Giampaolo Bianchini, MDSpeaks about Harnessing the TNBC Microenvironment to Integrate Novel Predictive Biomarkers

The discussion was on Tuesday, December 7, 2021Optimizing Immunotherapy in Triple-Negative Breast Cancer: Novel Predictive Biomarkers and Blood-Basted Efficacy Monitoring Speakers -Adam Brufsky, MD, PhDSpeaks about Navigating Treatment Decision Points in Management of TNBC: Interactive Case StudiesGiampaolo Bianchini, MDSpeaks about Harnessing the TNBC Microenvironment to Integrate Novel Predictive BiomarkersHope Rugo, MDSpeaks about Callenges and Opportunities for Optimizing Immunotherapies for TNBC

Peter Cole, MD, Rutgers Cancer Institute of New Jersey Embrace Kids Foundation Endowed Chair in Pediatric Hematology/Oncology and Chief of the Division of Pediatric Hematology/Oncology, also affiliated with Robert Wood Johnson University Hospital speaks about the ASH 2021 Abstract – 3485 Performance of Next Generation Sequencing for Minimal Residual Disease Detection for Pediatric Patients with Acute Lymphoblastic Leukemia: Results from the Prospective Clinical Trial DFCI 16-001.Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper152369.htmlOverview:In juvenile acute lymphoblastic leukemia, a sensitive and early assessment of minimal residual disease (MRD) is critical for risk classification (ALL). To detect MRD at the level of 1 leukemic cell in a…

Peter Cole, MD, Rutgers Cancer Institute of New Jersey Embrace Kids Foundation Endowed Chair in Pediatric Hematology/Oncology and Chief of the Division of Pediatric Hematology/Oncology, also affiliated with Robert Wood Johnson University Hospital speaks about the ASH 2021 Abstract – 3485 Performance of Next Generation Sequencing for Minimal Residual Disease Detection for Pediatric Patients with Acute Lymphoblastic Leukemia: Results from the Prospective Clinical Trial DFCI 16-001.Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper152369.htmlOverview:In juvenile acute lymphoblastic leukemia, a sensitive and early assessment of minimal residual disease (MRD) is critical for risk classification (ALL). To detect MRD at the level of 1 leukemic cell in a…

Philippe Moreau, MD, is Head of the Hematology Department at the University Hospital of Nantes, France speaks about the ASH 2021 Abstract 896 Updated Results from MajesTEC-1: Phase 1/2 Study of Teclistamab, a B-Cell Maturation Antigen x CD3 Bispecific Antibody, in Relapsed/Refractory Multiple Myeloma.Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper147915.htmlIntroduction:Teclistamab (JNJ-64007957) is a bispecific IgG4 T-cell redirection antibody that binds both BCMA and CD3 receptors to induce T-cell mediated cytotoxicity of BCMA-expressing myeloma cells. MajesTEC-1, an ongoing phase 1/2 research in patients with extensively pretreated relapsed/refractory multiple myeloma, is testing teclistamab (RRMM). After a median of 6.1 months of follow-up, results from the phase…

Philippe Moreau, MD, is Head of the Hematology Department at the University Hospital of Nantes, France speaks about the ASH 2021 Abstract 896 Updated Results from MajesTEC-1: Phase 1/2 Study of Teclistamab, a B-Cell Maturation Antigen x CD3 Bispecific Antibody, in Relapsed/Refractory Multiple Myeloma.Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper147915.htmlIntroduction:Teclistamab (JNJ-64007957) is a bispecific IgG4 T-cell redirection antibody that binds both BCMA and CD3 receptors to induce T-cell mediated cytotoxicity of BCMA-expressing myeloma cells. MajesTEC-1, an ongoing phase 1/2 research in patients with extensively pretreated relapsed/refractory multiple myeloma, is testing teclistamab (RRMM). After a median of 6.1 months of follow-up, results from the phase…

Adam M. Brufsky, MD, Ph.D., Professor of Medicine, Associate Chief, Division of Hematology/Oncology, Co-Director, Comprehensive Breast Cancer Center, Associate Director, Clinical Investigation at Magee-Womens Cancer Program, part of the UPMC Hillman Cancer Center of Medicine speaks about the Phase III DetermaIOâ„¢ Study.Description in detail:Mononuclear cells and lymphocytes have been found in numerous triple negative and basal-like breast tumors, according to new research. Regardless of the kind of tumor invasion by mononuclear cells, immune regulatory checkpoints like PD-1 and its ligand B7-H1 (or PD-L1) have a deleterious impact on treatment outcomes. These findings imply that PD-L1 expression is an adaptive strategy…

Adam M. Brufsky, MD, Ph.D., Professor of Medicine, Associate Chief, Division of Hematology/Oncology, Co-Director, Comprehensive Breast Cancer Center, Associate Director, Clinical Investigation at Magee-Womens Cancer Program, part of the UPMC Hillman Cancer Center of Medicine speaks about the Phase III DetermaIOâ„¢ Study.Description in detail:Mononuclear cells and lymphocytes have been found in numerous triple negative and basal-like breast tumors, according to new research. Regardless of the kind of tumor invasion by mononuclear cells, immune regulatory checkpoints like PD-1 and its ligand B7-H1 (or PD-L1) have a deleterious impact on treatment outcomes. These findings imply that PD-L1 expression is an adaptive strategy…

Alexis Combes, Ph.D., Director of Disease to Biology Colab at UCSF, Assistant professor department of pathology speaks about Sorting Cancers by “Immune Archetypes” Represents Potential New Approach to Developing Precision Immunotherapies.Link to Article:https://medicalxpress.com/news/2022-01-cancers-immune-archetypes-potential-approach.htmlLink to Study:https://authors.elsevier.com/c/1eJiWL7PXf0ZuSynopsisCancers differ significantly in terms of origin tissue, driver mutations, and other aspects of the surrounding tissue. Individual tumors are likely to engage common immune system patterns, or “archetypes,” to create prototype non-destructive tumor immune microenvironments (TMEs) and modulate tumor-targeting. The Immunoprofiler Initiative (IPI) at the University of California, San Francisco (UCSF) evaluated 364 unique tumors across 12 cancer types using standardized techniques to discover the…

Alexis Combes, Ph.D., Director of Disease to Biology Colab at UCSF, Assistant professor department of pathology speaks about Sorting Cancers by “Immune Archetypes” Represents Potential New Approach to Developing Precision Immunotherapies.Link to Article:https://medicalxpress.com/news/2022-01-cancers-immune-archetypes-potential-approach.htmlLink to Study:https://authors.elsevier.com/c/1eJiWL7PXf0ZuSynopsisCancers differ significantly in terms of origin tissue, driver mutations, and other aspects of the surrounding tissue. Individual tumors are likely to engage common immune system patterns, or “archetypes,” to create prototype non-destructive tumor immune microenvironments (TMEs) and modulate tumor-targeting. The Immunoprofiler Initiative (IPI) at the University of California, San Francisco (UCSF) evaluated 364 unique tumors across 12 cancer types using standardized techniques to discover the…

Brad S. Kahl, MD, Professor of Medicine, Division of Oncology, Washington University School of Medicine in St. Louis speaks about the ASH 2021 Abstract 815 Long Term Follow up of the Resort Study (E4402): A Randomized Phase III Study Comparing Two Different Rituximab Dosing Strategies for Low Tumor Burden Follicular Lymphoma. Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper152976.htmlContext:E4402 was a randomized phase III trial that compared two alternative rituximab dosing techniques for individuals with low tumor burden follicular lymphoma who had previously been untreated (FL). The time to treatment failure was the primary outcome. The first study (Kahl, JCO 2014) found that a retreatment…

Brad S. Kahl, MD, Professor of Medicine, Division of Oncology, Washington University School of Medicine in St. Louis speaks about the ASH 2021 Abstract 815 Long Term Follow up of the Resort Study (E4402): A Randomized Phase III Study Comparing Two Different Rituximab Dosing Strategies for Low Tumor Burden Follicular Lymphoma. Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper152976.htmlContext:E4402 was a randomized phase III trial that compared two alternative rituximab dosing techniques for individuals with low tumor burden follicular lymphoma who had previously been untreated (FL). The time to treatment failure was the primary outcome. The first study (Kahl, JCO 2014) found that a retreatment…

Yishai Ofran, MD, Director of Hematology department and Shaare Zedek Medical Center Jerusalem speaks about the ASH 2021 Abstract – 413 Allogeneic Transplantation in Fit Older Adults Is Feasible and Encouragingly Efficacious. Post Remission Data from the Prospective ECOG-ACRIN (E2906) Clinical Study.Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper149356.htmlIntroduction:The most effective anti-leukemia treatment after remission is allogeneic stem cell transplantation (alloSCT). However, the accompanying toxicity is a deterrent to its widespread use as standard of care in the elderly. Because randomized controlled trials comparing transplantation to non-transplantation are difficult to conduct, most studies of AML patients who had alloSCT are retrospective. The results of E2906,…

Yishai Ofran, MD, Director of Hematology department and Shaare Zedek Medical Center Jerusalem speaks about the ASH 2021 Abstract – 413 Allogeneic Transplantation in Fit Older Adults Is Feasible and Encouragingly Efficacious. Post Remission Data from the Prospective ECOG-ACRIN (E2906) Clinical Study.Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper149356.htmlIntroduction:The most effective anti-leukemia treatment after remission is allogeneic stem cell transplantation (alloSCT). However, the accompanying toxicity is a deterrent to its widespread use as standard of care in the elderly. Because randomized controlled trials comparing transplantation to non-transplantation are difficult to conduct, most studies of AML patients who had alloSCT are retrospective. The results of E2906,…

Marco Ruella, MD, Assistant Professor of Medicine in the Division of Hematology/Oncology and the Center for Cellular Immunotherapies and Scientific Director of the Lymphoma Program at the Hospital of the University of Pennsylvania speaks about the ASH 2021 Abstract 163 Gut Microbiota Tuning Promotes Tumor-Associated Antigen Cross Presentation and Enhances CAR T Antitumor Effects and 253 The Intestinal Microbiota Correlates with Response and Toxicity after CAR T Cell Therapy in Patients with B-Cell Malignancies.Link to Abstract 163:https://ash.confex.com/ash/2021/webprogram/Paper151093.htmlLink to Clinical Trial:https://clinicaltrials.gov/ct2/show/NCT02030847Link to Abstract 253:https://ash.confex.com/ash/2021/webprogram/Paper153945.html

Marco Ruella, MD, Assistant Professor of Medicine in the Division of Hematology/Oncology and the Center for Cellular Immunotherapies and Scientific Director of the Lymphoma Program at the Hospital of the University of Pennsylvania speaks about the ASH 2021 Abstract 163 Gut Microbiota Tuning Promotes Tumor-Associated Antigen Cross Presentation and Enhances CAR T Antitumor Effects and 253 The Intestinal Microbiota Correlates with Response and Toxicity after CAR T Cell Therapy in Patients with B-Cell Malignancies.Link to Abstract 163:https://ash.confex.com/ash/2021/webprogram/Paper151093.htmlLink to Clinical Trial:https://clinicaltrials.gov/ct2/show/NCT02030847Link to Abstract 253:https://ash.confex.com/ash/2021/webprogram/Paper153945.html

J. Joseph Melenhorst, Ph.D., Research Professor of Pathology and Laboratory Medicine Department: Pathology and Laboratory Medicine from the University of Pennsylvania speaks about the ASH 2021 Abstract 166 Decade-Long Remissions of Leukemia Sustained By the Persistence of Activated CD4+ CAR T-Cells.Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper152664.htmlAdoptive transfer of chimeric antigen receptor (CAR)-reprogrammed T cells has shown promise in treating a variety of cancers. In chronic lymphocytic leukemia (CLL), functional persistence of CAR T-cells is a crucial predictor of long-term remissions, although the properties of long-term persistent CAR-engineered T cells have not been fully investigated. The fate of CD19-specific (CAR19) T-cells in two leukemia…

J. Joseph Melenhorst, Ph.D., Research Professor of Pathology and Laboratory Medicine Department: Pathology and Laboratory Medicine from the University of Pennsylvania speaks about the ASH 2021 Abstract 166 Decade-Long Remissions of Leukemia Sustained By the Persistence of Activated CD4+ CAR T-Cells.Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper152664.htmlAdoptive transfer of chimeric antigen receptor (CAR)-reprogrammed T cells has shown promise in treating a variety of cancers. In chronic lymphocytic leukemia (CLL), functional persistence of CAR T-cells is a crucial predictor of long-term remissions, although the properties of long-term persistent CAR-engineered T cells have not been fully investigated. The fate of CD19-specific (CAR19) T-cells in two leukemia…

Adam M. Brufsky, MD, Ph.D., Professor of Medicine, Associate Chief, Division of Hematology/Oncology, Co-Director, Comprehensive Breast Cancer Center, Associate Director, Clinical Investigation at Magee-Womens Cancer Program, part of the UPMC Hillman Cancer Center of Medicine speaks about the Phase III DetermaIOâ„¢ Study.Link to Study:https://clinicaltrials.gov/ct2/show/NCT02620280Description in detail:Mononuclear cells and lymphocytes have been found in numerous triple negative and basal-like breast tumors, according to new research. Regardless of the kind of tumor invasion by mononuclear cells, immune regulatory checkpoints like PD-1 and its ligand B7-H1 (or PD-L1) have a deleterious impact on treatment outcomes. These findings imply that PD-L1 expression is an…

Lindsey E. Roeker, MD Hematologist Oncologist from Memorial Sloan Kettering Cancer Center speaks about the ASH 2021 Abstract – A Phase 2 Study Evaluating the Addition of Ublituximab and Umbralisib (U2) to Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL): A Minimal Residual Disease (MRD)-Driven, Time-Limited Approach.Link to Abstract:https://www.sciencedirect.com/science/article/abs/pii/S0006497121023892#!A summary -Context:While time-limited new agent combinations have shown good overall response rates and long-term responses in patients with chronic lymphocytic leukemia (CLL), they also have a high rate of adverse events and may overtreat many patients who are at low risk. Patients on indefinite ibrutinib monotherapy, on the other hand, are at…

Lindsey E. Roeker, MD Hematologist Oncologist from Memorial Sloan Kettering Cancer Center speaks about the ASH 2021 Abstract – A Phase 2 Study Evaluating the Addition of Ublituximab and Umbralisib (U2) to Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL): A Minimal Residual Disease (MRD)-Driven, Time-Limited Approach.Link to Abstract:https://www.sciencedirect.com/science/article/abs/pii/S0006497121023892#!A summary -Context:While time-limited new agent combinations have shown good overall response rates and long-term responses in patients with chronic lymphocytic leukemia (CLL), they also have a high rate of adverse events and may overtreat many patients who are at low risk. Patients on indefinite ibrutinib monotherapy, on the other hand, are at…

Neha Vapiwala, MD Professor of Radiation Oncology at the Hospital of the University of PennsylvaniaDepartment: Radiation Oncology, Penn Medicine speaks about the From JAMA Oncology – Diversity Trends by Sex and Underrepresented in Medicine Status Among US Radiation and Medical Oncology Faculty Over 5 Decades.Link to Abstract:https://pubmed.ncbi.nlm.nih.gov/34882189/A summary -Significance:It’s unclear how the historical exclusion of women and racial and ethnic minorities from medical school and, as a result, oncologic subspecialties, has influenced faculty diversity in oncology departments over time. Oncologic faculty diversity is a critical strategy for improving cancer care and addressing health inequities in an increasingly diverse US cancer community.Goals:To…

Neha Vapiwala, MD Professor of Radiation Oncology at the Hospital of the University of PennsylvaniaDepartment: Radiation Oncology, Penn Medicine speaks about the JAMA Oncology -  Diversity Trends by Sex and Underrepresented in Medicine Status Among US Radiation and Medical Oncology Faculty Over 5 Decades. Link to Abstract:https://pubmed.ncbi.nlm.nih.gov/34882189/A summary -Significance:It’s unclear how the historical exclusion of women and racial and ethnic minorities from medical school and, as a result, oncologic subspecialties, has influenced faculty diversity in oncology departments over time. Oncologic faculty diversity is a critical strategy for improving cancer care and addressing health inequities in an increasingly diverse US cancer community.Goals:To describe…

Dr. Stephen Malamud is the regional director of medical oncology at Nuvance Health. He is a board-certified and fellowship-trained physician who specializes in medical oncology for breast cancer. As an active clinical researcher, Dr. Malamud has been involved in trials that resulted in the approval of new cancer treatments. He is a nationally and internationally sought-after speaker. Dr. Malamud came from Mount Sinai Beth Israel Medical Center in New York before joining Nuvance Health. In this video he speaks about – An update of the targeted therapies for Her-2 and TNBC cancers with emphasis on the Destiny Trial (Enhertu) in…

Dr. Stephen Malamud is the regional director of medical oncology at Nuvance Health. He is a board-certified and fellowship-trained physician who specializes in medical oncology for breast cancer. As an active clinical researcher, Dr. Malamud has been involved in trials that resulted in the approval of new cancer treatments. He is a nationally and internationally sought-after speaker. Dr. Malamud came from Mount Sinai Beth Israel Medical Center in New York before joining Nuvance Health. In this video he speaks about – An update of the targeted therapies for Her-2 and TNBC cancers with emphasis on the Destiny Trial (Enhertu) in…

Saad Z. Usmani, MD MBA FACP, Chief, Myeloma Service at Memorial Sloan Kettering Cancer Center speaks about New Data from MajesTEC-1 Study Show Continued Deep and Durable Responses of Teclistamab (BCMAxCD3 Bispecific Antibody) in Treatment of Heavily Pretreated Patients with Multiple Myeloma.Link to Article:https://www.prnewswire.com/news-releases/new-data-from-majestec-1-study-show-continued-deep-and-durable-responses-of-teclistamab-bcmaxcd3-bispecific-antibody-in-treatment-of-heavily-pretreated-patients-with-multiple-myeloma-301443200.htmlThe MajesTEC-1 study of teclistamab, an off-the-shelf T-cell experimental redirecting bispecific antibody, is being evaluated for the treatment of patients with relapsed or refractory multiple myeloma. An overall response rate (ORR) of 62 percent was observed in heavily pretreated patients (n=150) across the Phase 1 and 2 studies who had received at least three prior lines of…

Saad Z. Usmani, MD MBA FACP, Chief, Myeloma Service at Memorial Sloan Kettering Cancer Center speaks about New Data from MajesTEC-1 Study Show Continued Deep and Durable Responses of Teclistamab (BCMAxCD3 Bispecific Antibody) in Treatment of Heavily Pretreated Patients with Multiple Myeloma.Link to Article:https://www.prnewswire.com/news-releases/new-data-from-majestec-1-study-show-continued-deep-and-durable-responses-of-teclistamab-bcmaxcd3-bispecific-antibody-in-treatment-of-heavily-pretreated-patients-with-multiple-myeloma-301443200.htmlThe MajesTEC-1 study of teclistamab, an off-the-shelf T-cell experimental redirecting bispecific antibody, is being evaluated for the treatment of patients with relapsed or refractory multiple myeloma. An overall response rate (ORR) of 62 percent was observed in heavily pretreated patients (n=150) across the Phase 1 and 2 studies who had received at least three prior lines of…

Colin C. Pritchard, MD, Professor, Co-Director, Genetics, and Solid Tumors Laboratory, Precision Diagnostics Platform Head, Brotman Baty Institute For Precision Medicine, UW Medicine Laboratory Medicine & Pathology. In this video speaks about Inherited TP53 Variants and Risk of Prostate Cancer.Link to Article:https://newsroom.uw.edu/news/inherited-mutation-linked-aggressive-prostate-cancerLink to Study:https://www.sciencedirect.com/science/article/pii/S0302283821021394?via%3DihubAbstract:Backstory:Autosomal dominant multicancer predisposition, including Li-Fraumeni syndrome, is caused by inherited germline TP53 pathogenic and possibly pathogenic mutations (gTP53) (LFS). However, there is no documented link between gTP53 and prostate cancer.Goal:To see if gTP53 plays a role in prostate cancer predisposition.Participants, setting, and design:The incidence of prostate cancer in a cohort of LFS males and the prevalence…

Colin C. Pritchard, MD, Professor, Co-Director, Genetics, and Solid Tumors Laboratory, Precision Diagnostics Platform Head, Brotman Baty Institute For Precision Medicine, UW Medicine Laboratory Medicine & Pathology. In this video speaks about Inherited TP53 Variants and Risk of Prostate Cancer.Link to Article:https://newsroom.uw.edu/news/inherited-mutation-linked-aggressive-prostate-cancerLink to Study:https://www.sciencedirect.com/science/article/pii/S0302283821021394?via%3DihubAbstract:Backstory:Autosomal dominant multicancer predisposition, including Li-Fraumeni syndrome, is caused by inherited germline TP53 pathogenic and possibly pathogenic mutations (gTP53) (LFS). However, there is no documented link between gTP53 and prostate cancer.Goal:To see if gTP53 plays a role in prostate cancer predisposition.Participants, setting, and design:The incidence of prostate cancer in a cohort of LFS males and the prevalence…

Jason Luke, MD, FACP, Director, Cancer Immunotherapeutics Center at UPMC Hillman Cancer Center speaks about FDA Approves Merck’s KEYTRUDA® (pembrolizumab) as Adjuvant Treatment for Adult and Pediatric (≥12 Years of Age) Patients With Stage IIB or IIC Melanoma Following Complete Resection.Link to Article:https://www.merck.com/news/fda-approves-mercks-keytruda-pembrolizumab-as-adjuvant-treatment-for-adult-and-pediatric-%e2%89%a512-years-of-age-patients-with-stage-iib-or-iic-melanoma-following-complete-resectio/The US Food and Drug Administration (FDA) has approved Merck’s anti-PD-1 medication, KEYTRUDA, for the adjuvant treatment of adult and pediatric (12 years and older) patients with stage IIB or IIC melanoma following full resection. The FDA also increased the indication for KEYTRUDA as an adjuvant treatment for stage III melanoma after full resection to include pediatric patients…

Jason Luke, MD, FACP, Director, Cancer Immunotherapeutics Center at UPMC Hillman Cancer Center speaks about FDA Approves Merck’s KEYTRUDA® (pembrolizumab) as Adjuvant Treatment for Adult and Pediatric (≥12 Years of Age) Patients With Stage IIB or IIC Melanoma Following Complete Resection.Link to Article:https://www.merck.com/news/fda-approves-mercks-keytruda-pembrolizumab-as-adjuvant-treatment-for-adult-and-pediatric-%e2%89%a512-years-of-age-patients-with-stage-iib-or-iic-melanoma-following-complete-resectio/The US Food and Drug Administration (FDA) has approved Merck’s anti-PD-1 medication, KEYTRUDA, for the adjuvant treatment of adult and pediatric (12 years and older) patients with stage IIB or IIC melanoma following full resection. The FDA also increased the indication for KEYTRUDA as an adjuvant treatment for stage III melanoma after full resection to include pediatric patients…

Jacob Laubach, MD, MPP from the Dana-Farber Cancer Institute speaks about the ASH 2021 Abstract – 79 Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients (Pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of Griffin after 24 Months of Maintenance.Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper149024.htmlIntroduction:DARA is approved for NDMM and MM that have been previously treated. DARA plus RVd (D-RVd) improved the rate of stringent complete response (sCR) by the end of post-ASCT consolidation versus RVd (42.4 percent vs 32.0 percent, 1-sided P=0.068) in the primary analysis of the phase 2 GRIFFIN trial (NCT02874742) in autologous stem cell transplant…

Jacob Laubach, MD, MPP from the Dana-Farber Cancer Institute speaks about the ASH 2021 Abstract – 79 Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients (Pts) with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM): Updated Analysis of Griffin after 24 Months of Maintenance.Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper149024.htmlIntroduction:DARA is approved for NDMM and MM that have been previously treated. DARA plus RVd (D-RVd) improved the rate of stringent complete response (sCR) by the end of post-ASCT consolidation versus RVd (42.4 percent vs 32.0 percent, 1-sided P=0.068) in the primary analysis of the phase 2 GRIFFIN trial (NCT02874742) in autologous stem cell transplant…

Javier Cortés, MD, Ph.D., Founder, and director of the International Breast Cancer Center (IBCC), in Madrid, Spain. Dr. Javier Cortés Castán is a leading oncologist of international renown in the research and treatment of breast cancer. Speaks about the SABCS 2021 Abstract – GS1-02 Final results of KEYNOTE-355: Randomized, double-blind, phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer.Link to Abstract:https://www.sabcs.org/Portals/SABCS2016/2021%20SABCS/SABCS%202021%20Abstracts.pdf?ver=2021-11-19-080202-743&utm_source=Jaguar+Health%2C+Inc.+Investor+Contacts&utm_campaign=8777ae34f6-Earnings+Call+111417_COPY_01&utm_medium=email&utm_term=0_4612a17168-8777ae34f6-610272854&mc_cid=8777ae34f6&mc_eid=3a5efd49f4

Javier Cortés, MD, Ph.D., Founder, and director of the International Breast Cancer Center (IBCC), in Madrid, Spain. Dr. Javier Cortés Castán is a leading oncologist of international renown in the research and treatment of breast cancer. Speaks about the SABCS 2021 Abstract – GS1-02 Final results of KEYNOTE-355: Randomized, double-blind, phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer.Link to Abstract:https://www.sabcs.org/Portals/SABCS2016/2021%20SABCS/SABCS%202021%20Abstracts.pdf?ver=2021-11-19-080202-743&utm_source=Jaguar+Health%2C+Inc.+Investor+Contacts&utm_campaign=8777ae34f6-Earnings+Call+111417_COPY_01&utm_medium=email&utm_term=0_4612a17168-8777ae34f6-610272854&mc_cid=8777ae34f6&mc_eid=3a5efd49f4

Ruben A. Mesa, MD, FACP from Mays Cancer Center, UT Health San Antonio Cancer Center speaks about the ASH 2021 Abstract – 1490 INDEPENDENCE: A Phase 3 Study of Efficacy and Safety of Luspatercept Versus Placebo in Patients with Myeloproliferative Neoplasm-Associated Myelofibrosis on JAK2 Inhibitor Therapy and Requiring Red Blood Cell Transfusions.Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper145717.htmlBackground:Ineffective erythropoiesis, faulty bone marrow (BM) function, and fibrosis, and a higher likelihood of progression to acute myeloid leukemia are all symptoms of myeloproliferative neoplasm (MPN)-associated myelofibrosis (MF) (AML). Anemia is present in up to 60% of patients (pts) at the time of diagnosis, and all pts…

Ruben A. Mesa, MD, FACP from Mays Cancer Center, UT Health San Antonio Cancer Center speaks about the ASH 2021 Abstract – 1490 INDEPENDENCE: A Phase 3 Study of Efficacy and Safety of Luspatercept Versus Placebo in Patients with Myeloproliferative Neoplasm-Associated Myelofibrosis on JAK2 Inhibitor Therapy and Requiring Red Blood Cell Transfusions.Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper145717.htmlBackground:Ineffective erythropoiesis, faulty bone marrow (BM) function, and fibrosis, and a higher likelihood of progression to acute myeloid leukemia are all symptoms of myeloproliferative neoplasm (MPN)-associated myelofibrosis (MF) (AML). Anemia is present in up to 60% of patients (pts) at the time of diagnosis, and all pts…

Sara Tolaney, MD from Dana Farber Cancer Institute speaks about the SABCS 2021 Presentation – Heterogeneity in treatment outcomes for HER2+ breast cancer – clinical management strategies.

Sara Tolaney, MD from Dana Farber Cancer Institute speaks about the SABCS 2021 Presentation – Heterogeneity in treatment outcomes for HER2+ breast cancer – clinical management strategies.

Courtney D. DiNardo, MD, MSCE, is a clinical researcher who focuses on prognostication and customized treatments for myeloid malignancies patients at The University of Texas Anderson Cancer Center. Speaks about the ASH 2021 Abstract – 1243 Outcomes for Patients with Late-Stage Mutant-IDH2 (mIDH2) Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) Treated with Enasidenib Vs Other Lower-Intensity Therapies in the Randomized, Phase 3 IDHentify Trial.Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper147593.htmlBackground:For older patients (pts) with R/R AML, the prognosis is poor, especially if numerous lines of AML treatment (Tx) have failed. After each Tx failure, achieving a response becomes increasingly difficult, and many patients are unable…

Courtney D. DiNardo, MD, MSCE, is a clinical researcher who focuses on prognostication and customized treatments for myeloid malignancies patients at The University of Texas Anderson Cancer Center. Speaks about the ASH 2021 Abstract – 1243 Outcomes for Patients with Late-Stage Mutant-IDH2 (mIDH2) Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) Treated with Enasidenib Vs Other Lower-Intensity Therapies in the Randomized, Phase 3 IDHentify Trial.Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper147593.htmlBackground:For older patients (pts) with R/R AML, the prognosis is poor, especially if numerous lines of AML treatment (Tx) have failed. After each Tx failure, achieving a response becomes increasingly difficult, and many patients are unable…

Geoffrey B. Pelz, MD, Thoracic Surgical Oncology, Hackensack Meridian Health speaks about the New GPS-Like Technology to Detect & Help Treat Lung Cancer at Hackensack University Medical Center.Link to Article:http://www.amboyguardian.com/2021/10/08/new-gps-like-technology-to-detect-help-treat-lung-cancer-at-hackensack-university-medical-centerAs we approach World Lung Day on September 25, 2021, a day dedicated to raising awareness about the importance of lung health, lung cancer remains the leading cause of cancer death for both men and women in the United States, owing to its difficulty in early detection.Certain lung lesions may be dangerous or impossible to identify with typical biopsy techniques. As a result, lung cancer can progress before it is discovered.While…

Geoffrey B. Pelz, MD, Thoracic Surgical Oncology, Hackensack Meridian Health speaks about the New GPS-Like Technology to Detect & Help Treat Lung Cancer at Hackensack University Medical Center.Link to Article:http://www.amboyguardian.com/2021/10/08/new-gps-like-technology-to-detect-help-treat-lung-cancer-at-hackensack-university-medical-centerAs we approach World Lung Day on September 25, 2021, a day dedicated to raising awareness about the importance of lung health, lung cancer remains the leading cause of cancer death for both men and women in the United States, owing to its difficulty in early detection.Certain lung lesions may be dangerous or impossible to identify with typical biopsy techniques. As a result, lung cancer can progress before it is discovered.While…

Maureen M. Achebe, MD, MPH, Associate Physician, Brigham and Women’s Hospital, Assistant Professor of Medicine, Harvard Medical School, Associate Director, Brigham and Women’s Hospital Infusion Center speaks about the ASH 2021 Abstract – 3114 Long-Term Safety and Efficacy of Voxelotor for Patients with Sickle Cell Disease: Results from an Open-Label Extension of the Phase 3 HOPE Trial.Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper153582.htmlBackground:Sickle cell disease (SCD) is a lifelong inherited blood illness caused by a mutation in the hemoglobin (Hb) subunit gene, which results in the development of sickle hemoglobin (HbS). Hemolysis, chronic anemia, and vaso-occlusive crises are all caused by HbS polymerization, which…

Maureen M. Achebe, MD, MPH, Associate Physician, Brigham and Women’s Hospital, Assistant Professor of Medicine, Harvard Medical School, Associate Director, Brigham and Women’s Hospital Infusion Center speaks about the ASH 2021 Abstract – 3114 Long-Term Safety and Efficacy of Voxelotor for Patients with Sickle Cell Disease: Results from an Open-Label Extension of the Phase 3 HOPE Trial.Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper153582.htmlBackground:Sickle cell disease (SCD) is a lifelong inherited blood illness caused by a mutation in the hemoglobin (Hb) subunit gene, which results in the development of sickle hemoglobin (HbS). Hemolysis, chronic anemia, and vaso-occlusive crises are all caused by HbS polymerization, which…

Sara A. Hurvitz, MD, Assistant Professor of Medicine, Division of Hematology/Oncology, David Geffen School of Medicine at UCLA speaks about the SABCS 2021 Abstract – GS3-01 Trastuzumab deruxtecan (T-DXd; DS-8201a) vs. trastuzumab emtansine (T-DM1) in patients (pts) with HER2+ metastatic breast cancer (mBC): subgroup analyses from the randomized phase 3 study DESTINY-Breast03.Link to Abstract:https://www.sabcs.org/Portals/SABCS2016/2021%20SABCS/SABCS%202021%20Abstracts.pdf?ver=2021-11-19-080202-743&utm_source=Jaguar+Health%2C+Inc.+Investor+Contacts&utm_campaign=8777ae34f6-Earnings+Call+111417_COPY_01&utm_medium=email&utm_term=0_4612a17168-8777ae34f6-610272854&mc_cid=8777ae34f6&mc_eid=3a5efd49f4

Sara A. Hurvitz, MD, Assistant Professor of Medicine, Division of Hematology/Oncology, David Geffen School of Medicine at UCLA speaks about the SABCS 2021 Abstract – GS3-01 Trastuzumab deruxtecan (T-DXd; DS-8201a) vs. trastuzumab emtansine (T-DM1) in patients (pts) with HER2+ metastatic breast cancer (mBC): subgroup analyses from the randomized phase 3 study DESTINY-Breast03.Link to Abstract:https://www.sabcs.org/Portals/SABCS2016/2021%20SABCS/SABCS%202021%20Abstracts.pdf?ver=2021-11-19-080202-743&utm_source=Jaguar+Health%2C+Inc.+Investor+Contacts&utm_campaign=8777ae34f6-Earnings+Call+111417_COPY_01&utm_medium=email&utm_term=0_4612a17168-8777ae34f6-610272854&mc_cid=8777ae34f6&mc_eid=3a5efd49f4

Marwan Fakih, MD, The Judy & Bernard Briskin Distinguished Director of Clinical Research; Professor, Department of Medical Oncology & Therapeutics Research; Associate Director for Clinical Research, Comprehensive Cancer Center; Medical Director, Judy & Bernard Briskin Center for Clinical Research; Co-director, Gastrointestinal Cancer Program at City of Hope. Speaks about Sotorasib for previously treated colorectal cancers with KRAS p.G12C mutation (CodeBreaK100): an interim analysis of a single-arm, Phase 2 trial.Link to Article:https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00605-7/fulltextBackstory:In the CodeBreaK100 phase 1 trial, sotorasib, a selective, irreversible KRASG12C protein inhibitor, showed monotherapy clinical activity in KRASG12C-mutated solid tumors, including colorectal cancer. In phase 2 of the trial,…

Marwan Fakih, MD, The Judy & Bernard Briskin Distinguished Director of Clinical Research; Professor, Department of Medical Oncology & Therapeutics Research; Associate Director for Clinical Research, Comprehensive Cancer Center; Medical Director, Judy & Bernard Briskin Center for Clinical Research; Co-director, Gastrointestinal Cancer Program at City of Hope. Speaks about Sotorasib for previously treated colorectal cancers with KRAS p.G12C mutation (CodeBreaK100): an interim analysis of a single-arm, Phase 2 trial.Link to Article:https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00605-7/fulltextBackstory:In the CodeBreaK100 phase 1 trial, sotorasib, a selective, irreversible KRASG12C protein inhibitor, showed monotherapy clinical activity in KRASG12C-mutated solid tumors, including colorectal cancer. In phase 2 of the trial,…

Mahmoud Elsawy, MD, MSc Assistant Professor, Division of Hematology, Dalhousie University. Medical Director of IEC Therapy Program, QEII Health Sciences Center, NS, Canada speaks about the ASH 2021 Abstract – 430 Patient-Reported Outcomes in a Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel (Axi-Cel) Versus Standard of Care Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma (ZUMA-7). Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper147598.htmlBackground:Patients with large B-cell lymphoma (LBCL) who relapse early or are unresponsive to first-line therapy have dismal outcomes. Furthermore, patients receiving second-line standard-of-care (SOC) therapy frequently report a low quality of life connected to their health (QoL; Lin…

Mahmoud Elsawy, MD, MSc Assistant Professor, Division of Hematology, Dalhousie University. Medical Director of IEC Therapy Program, QEII Health Sciences Center, NS, Canada speaks about the ASH 2021 Abstract – 430 Patient-Reported Outcomes in a Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel (Axi-Cel) Versus Standard of Care Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma (ZUMA-7).Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper147598.htmlBackground:Patients with large B-cell lymphoma (LBCL) who relapse early or are unresponsive to first-line therapy have dismal outcomes. Furthermore, patients receiving second-line standard-of-care (SOC) therapy frequently report a low quality of life connected to their health (QoL; Lin V,…

Avanish Vellanki, MBA and Robert Doebele, MD, Ph.D., Chief Executive Officer, and Co-founder, and President, Chief Scientific Officer & Co-founder of Rain Therapeutics discusses Rain Therapeutics Initiates Phase 3 MANTRA Clinical Trial of Milademetan for De-differentiated Liposarcoma and Provides Patient Update from Prior Clinical Program.Link to Article:https://www.globenewswire.com/news-release/2021/07/20/2265589/0/en/Rain-Therapeutics-Initiates-Phase-3-MANTRA-Clinical-Trial-of-Milademetan-for-De-differentiated-Liposarcoma-and-Provides-Patient-Update-from-Prior-Clinical-Program.htmlLink to Study:https://clinicaltrials.gov/ct2/show/NCT04979442Rain Therapeutics Inc., a clinical-stage company focused on precision oncology therapeutics, announced today that the first patient in the multicenter, open-label, Phase 3 registrational study (MANTRA) evaluating milademetan (RAIN-32), an oral mouse double minute 2 (MDM2) inhibitor, for the treatment of DD LPS has been randomized.The MANTRA trial is a randomized, multicenter,…

Avanish Vellanki, MBA and Robert Doebele, MD, Ph.D., Chief Executive Officer, and Co-founder, and President, Chief Scientific Officer & Co-founder of Rain Therapeutics discusses Rain Therapeutics Initiates Phase 3 MANTRA Clinical Trial of Milademetan for De-differentiated Liposarcoma and Provides Patient Update from Prior Clinical Program.Link to Article:https://www.globenewswire.com/news-release/2021/07/20/2265589/0/en/Rain-Therapeutics-Initiates-Phase-3-MANTRA-Clinical-Trial-of-Milademetan-for-De-differentiated-Liposarcoma-and-Provides-Patient-Update-from-Prior-Clinical-Program.htmlLink to Study:https://clinicaltrials.gov/ct2/show/NCT04979442Rain Therapeutics Inc., a clinical-stage company focused on precision oncology therapeutics, announced today that the first patient in the multicenter, open-label, Phase 3 registrational study (MANTRA) evaluating milademetan (RAIN-32), an oral mouse double minute 2 (MDM2) inhibitor, for the treatment of DD LPS has been randomized.The MANTRA trial is a randomized, multicenter,…

Matthew A. Ingham, MD, Assistant Professor of Medicine in the Division of Hematology and Oncology at Columbia University Vagelos College of Physicians and Surgeons speaks about Intensity Therapeutics Reports Use of INT230-6 Alone or in Combination with Ipilimumab Shows Evidence of Direct Tumor Necrosis and Promising Overall Survival Results in Adult Subjects with Metastatic Sarcomas at the Connective Tissue Oncology Society (CTOS) 2021 Virtual Annual Meeting.Intensity Therapeutics, Inc., a clinical-stage biotechnology company focused on the discovery and development of proprietary immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, announced today that data from…

Matthew A. Ingham, MD, Assistant Professor of Medicine in the Division of Hematology and Oncology at Columbia University Vagelos College of Physicians and Surgeons speaks about Intensity Therapeutics Reports Use of INT230-6 Alone or in Combination with Ipilimumab Shows Evidence of Direct Tumor Necrosis and Promising Overall Survival Results in Adult Subjects with Metastatic Sarcomas at the Connective Tissue Oncology Society (CTOS) 2021 Virtual Annual Meeting.Intensity Therapeutics, Inc., a clinical-stage biotechnology company focused on the discovery and development of proprietary immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, announced today that data from…

Terry Mamounas, MD, MPH, FACS from Orlando Health Cancer Institute speaks about the SABCS 2021 Presentation – Refining Axillary Management After Neoadjuvant Chemotherapy – What Does The Evidence Support.

Terry Mamounas, MD, MPH, FACS from Orlando Health Cancer Institute speaks about the SABCS 2021 Presentation – Refining Axillary Management After Neoadjuvant Chemotherapy – What Does The Evidence Support.

Karuppiah Kannan, Ph.D. Senior Director – Global Program Leader at Takeda Oncology speaks about the ASH 2021 Abstracts – 2488 TAK-981, a First-in-Class SUMO-Activating Enzyme Inhibitor, Combined with Rituximab in Adult Patients (Pts) with CD20-Positive Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL): Phase 1 Data, and 2742 Phase 1b/2 Study of the First-in-Class SUMO-Activating Enzyme Inhibitor TAK-981 in Combination with Monoclonal Antibodies in Patients with Triple-Class Refractory Multiple Myeloma.Link to Abstract 2488:https://ash.confex.com/ash/2021/webprogram/Paper152225.htmlBackground:TAK-981 is the first SUMOylation small-molecule inhibitor to reach clinical studies. Small ubiquitin-like modifier (SUMO) proteins are activated and covalently bound to substrate proteins during SUMOylation, a post-translational modification. Type I…

Karuppiah Kannan, Ph.D. Senior Director – Global Program Leader at Takeda Oncology speaks about the ASH 2021 Abstracts – 2488 TAK-981, a First-in-Class SUMO-Activating Enzyme Inhibitor, Combined with Rituximab in Adult Patients (Pts) with CD20-Positive Relapsed/Refractory (R/R) Non-Hodgkin Lymphoma (NHL): Phase 1 Data, and 2742 Phase 1b/2 Study of the First-in-Class SUMO-Activating Enzyme Inhibitor TAK-981 in Combination with Monoclonal Antibodies in Patients with Triple-Class Refractory Multiple Myeloma.Link to Abstract 2488:https://ash.confex.com/ash/2021/webprogram/Paper152225.htmlBackground:TAK-981 is the first SUMOylation small-molecule inhibitor to reach clinical studies. Small ubiquitin-like modifier (SUMO) proteins are activated and covalently bound to substrate proteins during SUMOylation, a post-translational modification. Type I…

Naval Daver, MD from The University of Texas MD Anderson Cancer Center speaks about the ASH 2021 Abstract – 3426 A Phase 3, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination with Azacitidine in Previously Untreated Patients with TP53-Mutant Acute Myeloid Leukemia.Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper145208.htmlBackground:Magrolimab (Hu5F9-G4) is an antibody that kills leukemia stem cells by encouraging tumor phagocytosis by inhibiting CD47, a macrophage immune checkpoint and “don’t eat me” signal on cancer cells. Hypomethylating drugs work along with magrolimab to increase phagocytosis by eliciting “eat me” signals on leukemic blasts. In frontline acute myeloid leukemia (AML) patients…

Study to Evaluate the Safety and Efficacy of Magrolimab in Combination With Azacitidine Versus Physician’s Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Previously Untreated Adults With TP53 Mutant Acute Myeloid Leukemia (ENHANCE-2 Clinical Trial) The study we are conducting here is a randomized phase 3 international study of Azacitidine Magrolimab (Hu5F9-G4), versus investigator choice therapy of either Azacitidine Venetoclax or intensive three plus seven, specifically in a molecular subset of TP53-mutated (TP53m), acute myeloid leukemia. The goal of this study is to see whether the combination treatment of Azacitidine with CD47 immune therapy Magrolimab (Hu5F9-G4) could…

Professor Jonathan Wall, Ph.D., Distinguished Professor and Director of the University of Tennessee Graduate School of Medicine’s Amyloidosis and Cancer Theranostics Program speaks about the ASH 2021 Abstract – 2952 Detection of Systemic AL Amyloidosis By 124I-p5+14 PET/CT Imaging – Providing the Complete Picture for Diagnosis.Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper154327.htmlBackground:The deposition of fibrils in abdominothoracic organs, particularly the heart, liver, spleen, and kidneys, is associated with Immunoglobulin light chain-associated (AL) amyloidosis, resulting in organ failure and substantial morbidity. The fluctuating quantities of amyloid load and the varied organ presentation of amyloid make accurate and speedy diagnosis difficult. Organ biopsy and inferences based…

Craig Eagle, MD, FRACP, FRCPA from Guardant Health. In this video, he explains that the Study Shows Guardant360® Liquid Biopsy Test Helps Guide Treatment for Patients with HER2-Driven Metastatic Colorectal Cancer. https://www.businesswire.com/news/home/20211111006023/en/Study-Shows-Guardant360%C2%AE-Liquid-Biopsy-Test-Helps-Guide-Treatment-for-Patients-with-HER2-Driven-Metastatic-Colorectal-CancerThe TRIUMPH study looked at the efficacy of pertuzumab with trastuzumab in patients with mCRC who had HER2 amplification as established by circulating tumor DNA (ctDNA) analysis or tissue genotyping. EGFR-targeting monoclonal antibodies had previously been used to treat all of the patients. Additional exploratory studies were conducted to explore if ctDNA genotyping might be used to predict treatment success, follow response, and uncover resistance mechanisms.While the efficacy of…

Professor Jonathan Wall, Ph.D., Distinguished Professor and Director of the University of Tennessee Graduate School of Medicine’s Amyloidosis and Cancer Theranostics Program speaks about the ASH 2021 Abstract – 2952 Detection of Systemic AL Amyloidosis By 124I-p5+14 PET/CT Imaging – Providing the Complete Picture for Diagnosis.Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper154327.htmlBackground:The deposition of fibrils in abdominothoracic organs, particularly the heart, liver, spleen, and kidneys, is associated with Immunoglobulin light chain-associated (AL) amyloidosis, resulting in organ failure and substantial morbidity. The fluctuating quantities of amyloid load and the varied organ presentation of amyloid make accurate and speedy diagnosis difficult. Organ biopsy and inferences based…

David Spiegel, MD from Stanford University speaks about the SABCS Presentation – Hypnosis and Mindfulness.Go to the links below to download the app. https://apps.apple.com/us/app/reveri/id1547020650https://play.google.com/store/apps/details?id=com.reveri.reverihealth&hl=en_US&gl=US

David Spiegel, MD from Stanford University speaks about the SABCS Presentation – Hypnosis and Mindfulness.Go to the links below to download the app. https://apps.apple.com/us/app/reveri/id1547020650https://play.google.com/store/apps/details?id=com.reveri.reverihealth&hl=en_US&gl=US

Erika P. Hamilton, MD, Director, Breast Cancer and Gynecologic Cancer Research, Sarah Cannon Research Institute at Tennessee Oncology speak about the SABCS 2021 Abstract – OT1-13-01 HER2CLIMB-04: phase 2 trial of tucatinib + trastuzumab deruxtecan in patients with HER2+ locally advanced or metastatic breast cancer with and without brain metastases.

Erika P. Hamilton, MD, Director, Breast Cancer and Gynecologic Cancer Research, Sarah Cannon Research Institute at Tennessee Oncology speak about the SABCS 2021 Abstract – OT1-13-01 HER2CLIMB-04: phase 2 trial of tucatinib + trastuzumab deruxtecan in patients with HER2+ locally advanced or metastatic breast cancer with and without brain metastases.

Elisha Hughes, Ph.D., Director of Research Biostatistics at Myriad Genetics, Inc. speaks about the SABCS Abstract – P2-11-21 Integration of an ancestrally unbiased polygenic risk score with the Tyrer-Cuzick breast cancer risk model.

Elisha Hughes, Ph.D., Director of Research Biostatistics at Myriad Genetics, Inc. speaks about the SABCS Abstract – P2-11-21 Integration of an ancestrally unbiased polygenic risk score with the Tyrer-Cuzick breast cancer risk model.

Ajeet Gajra, MD, FACS, Chief Medical Officer at Cardinal Health Specialty Solutions speaks about the ASH 2021 Abstract – 4010 Barriers to Referral for Chimeric Antigen Receptor T Cell (CAR-T) Therapies Among U.S. Community Hematologists/Oncologists (cH/O).Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper148165.htmlIntroduction:Gene therapies, which include inserting, removing, or changing genetic information into a patient’s cells to treat a specific disease, are a big step forward in medicine, with the potential to cure or greatly improve the outcomes of a variety of benign and malignant hematologic disorders (American Society of Gene Therapy). For subgroups of people with spinal muscular atrophy or retinal dystrophy, gene therapies…

Ajeet Gajra, MD, FACS, Chief Medical Officer at Cardinal Health Specialty Solutions speaks about the ASH 2021 Abstract – 4010 Barriers to Referral for Chimeric Antigen Receptor T Cell (CAR-T) Therapies Among U.S. Community Hematologists/Oncologists (cH/O).Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper148165.htmlIntroduction:Gene therapies, which include inserting, removing, or changing genetic information into a patient’s cells to treat a specific disease, are a big step forward in medicine, with the potential to cure or greatly improve the outcomes of a variety of benign and malignant hematologic disorders (American Society of Gene Therapy). For subgroups of people with spinal muscular atrophy or retinal dystrophy, gene therapies…

Bradley P. Dixon, MD, Renal Section, Department of Pediatrics, University of Colorado School of Medicine, Pediatric Nephrologist at Children’s Hospital Colorado speaks about the ASH 2021 Abstract – 769 Two-Year Efficacy and Safety of Ravulizumab in Adults and Children with Atypical Hemolytic Uremic Syndrome (aHUS): Analysis of Two Phase 3 Studies.Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper145040.htmlBackground:Ravulizumab, a humanized anti-complement C5 monoclonal antibody created by modifying eculizumab to attain a longer half-life, has been approved to treat aHUS in the United States (2019), the European Union (2019), and Japan (2020). The results of the phase 3 studies of ravulizumab in adults and children with…

Bradley P. Dixon, MD, Renal Section, Department of Pediatrics, University of Colorado School of Medicine, Pediatric Nephrologist at Children ‘s Hospital Colorado speaks about the ASH 2021 Abstract – 769 Two-Year Efficacy and Safety of Ravulizumab in Adults and Children with Atypical Hemolytic Uremic Syndrome (aHUS): Analysis of Two Phase 3 Studies.Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper145040.htmlBackground:Ravulizumab, a humanized anti-complement C5 monoclonal antibody created by modifying eculizumab to attain a longer half-life, has been approved to treat aHUS in the United States (2019), the European Union (2019), and Japan (2020). The results of the phase 3 studies of ravulizumab in adults and children…

Abdulraheem Yacoub, MD from the University of Kansas Center for Bioinformatics speaks about the ASH 2021 Abstract – 2579 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Ruxolitinib Plus Parsaclisib in Patients with JAK- and PI3K-Inhibitor Treatment–Naive Myelofibrosis.Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper148794.htmlBackground:Ruxolitinib is a Janus kinase (JAK)1/JAK2 inhibitor that improves myelofibrosis patient outcomes dramatically (MF). However, ruxolitinib alone may have an unsatisfactory response in some patients; deeper and longer-lasting responses in these patients could be achieved by combining ruxolitinib with medicines that target other signaling pathways involved in MF development. According to recent phase 2 results, adding the phosphatidylinositol 3 kinase (PI3K)…

Abdulraheem Yacoub, MD from the University of Kansas Center for Bioinformatics speaks about the ASH 2021 Abstract – 2579 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Ruxolitinib Plus Parsaclisib in Patients with JAK- and PI3K-Inhibitor Treatment–Naive Myelofibrosis.Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper148794.htmlBackground:Ruxolitinib is a Janus kinase (JAK)1/JAK2 inhibitor that improves myelofibrosis patient outcomes dramatically (MF). However, ruxolitinib alone may have an unsatisfactory response in some patients; deeper and longer-lasting responses in these patients could be achieved by combining ruxolitinib with medicines that target other signaling pathways involved in MF development. According to recent phase 2 results, adding the phosphatidylinositol 3 kinase (PI3K)…

Dr. Haythem Y. Ali is a cancer specialist in Troy, Michigan, and is linked with a number of local hospitals, including Henry Ford Hospital and Henry Ford West Bloomfield Hospital. He graduated from the University of Baghdad College of Medicine and has been practicing medicine for over 20 years. In this video Dr. Ali discusses P3-14-17 Exploring racial disparities in BRCA testing for triple negative breast cancer patients: A real-world data analysis.https://www.sabcs.org/Portals/SABCS2016/2021%20SABCS/SABCS%202021%20Abstracts.pdf?ver=2021-11-19-080202-743&utm_source=Jaguar+Health%2C+Inc.+Investor+Contacts&utm_campaign=8777ae34f6-Earnings+Call+111417_COPY_01&utm_medium=email&utm_term=0_4612a17168-8777ae34f6-610272854&mc_cid=8777ae34f6&mc_eid=3a5efd49f4The maximum limit of the Disclosure Block has been reached.Background: In patients with early-stage TNBC, KEYNOTE-522 (NCT03036488) is a phase 3 study comparing neoadjuvant pembro + chemo to placebo…

Dr. Haythem Y. Ali is a cancer specialist in Troy, Michigan, and is linked with a number of local hospitals, including Henry Ford Hospital and Henry Ford West Bloomfield Hospital. He graduated from the University of Baghdad College of Medicine and has been practicing medicine for over 20 years. In this video Dr. Ali discusses P3-14-17 Exploring racial disparities in BRCA testing for triple negative breast cancer patients: A real-world data analysis.https://www.sabcs.org/Portals/SABCS2016/2021%20SABCS/SABCS%202021%20Abstracts.pdf?ver=2021-11-19-080202-743&utm_source=Jaguar+Health%2C+Inc.+Investor+Contacts&utm_campaign=8777ae34f6-Earnings+Call+111417_COPY_01&utm_medium=email&utm_term=0_4612a17168-8777ae34f6-610272854&mc_cid=8777ae34f6&mc_eid=3a5efd49f4The maximum limit of the Disclosure Block has been reached.Background: In patients with early-stage TNBC, KEYNOTE-522 (NCT03036488) is a phase 3 study comparing neoadjuvant pembro + chemo to placebo…

Kirsten Timms, Ph.D., VP Biomarker Discovery at Myriad Genetics Inc speaks about SABCS 2021 Abstract – P5-13-09 Identifying homologous recombination deficiency in breast cancer: Genomic instability score thresholds differ in breast cancer subtypes.

Kirsten Timms, Ph.D., VP Biomarker Discovery at Myriad Genetics Inc speaks about SABCS 2021 Abstract – P5-13-09 Identifying homologous recombination deficiency in breast cancer: Genomic instability score thresholds differ in breast cancer subtypes.

Paolo Ghia earned his medical degree from the University of Torino and then completed an internal medicine residency. He earned his PhD studying the formation of normal human B cells at the Basel Institute for Immunology in Basel, Switzerland. He then went to Harvard Medical School’s Dana-Farber Cancer Institute in Boston, where he examined the molecular processes of chronic lymphoproliferative diseases, including follicular lymphoma. He is now a Full Professor of Medical Oncology at Università Vita-Salute San Raffaele and Deputy Chairman of the Division of Experimental Oncology at IRCCS Ospedale San Raffaele in Milano, where he is also Head of…

Paolo Ghia received his MD from the University of Torino, Italy, and received his PhD working at the Basel Institute for Immunology, Switzerland, studying B lymphocyte development. Next, he studied the molecular mechanisms of the pathogenesis of chronic lymphoproliferative disorders, particularly of follicular lymphoma at the Dana-Farber Cancer Institute, Harvard Medical School, Boston.   He is now working in Milano, as Professor of Medical Oncology at the Università Vita-Salute San Raffaele; and Deputy Chairman of the Division of Experimental Oncology, at the affiliated Hospital, where he is Director of the Strategic Research Program on CLL, including a dedicated unit for…

Dr. Jerome Goldschmidt graduated from the University of North Carolina School of Medicine with a bachelor of arts in German and a minor in chemistry. At the University of Rochester/Strong Memorial Hospital in Rochester, New York, he completed his medical oncology fellowship. In this video Dr. Goldschmidt discusses Understanding Hematological Adverse Event Management through Health Care Resource Utilization, Costs, and Treatment Patterns of Patients with Extensive-Stage Small Cell Lung Cancer Treated in the Community Oncology Setting.https://ash.confex.com/ash/2021/webprogram/Paper148057.htmlBACKGROUND:Chemotherapy-induced myelosuppressive hematological adverse events (anemia, neutropenia, and thrombocytopenia) are typical side effects in cancer patients. For patients with advanced stage small cell lung cancer,…

Dr. Jerome Goldschmidt graduated from the University of North Carolina School of Medicine with a bachelor of arts in German and a minor in chemistry. At the University of Rochester/Strong Memorial Hospital in Rochester, New York, he completed his medical oncology fellowship. In this video Dr. Goldschmidt discusses Understanding Hematological Adverse Event Management through Health Care Resource Utilization, Costs, and Treatment Patterns of Patients with Extensive-Stage Small Cell Lung Cancer Treated in the Community Oncology Setting.https://ash.confex.com/ash/2021/webprogram/Paper148057.htmlBACKGROUND:Chemotherapy-induced myelosuppressive hematological adverse events (anemia, neutropenia, and thrombocytopenia) are typical side effects in cancer patients. For patients with advanced stage small cell lung cancer,…

Dr. John Mascarenhas is a member of The Tisch Cancer Institute and a professor of medicine at Mount Sinai’s Icahn School of Medicine. He is also the director of the Center of Excellence for Blood Cancers and Myeloid Disorders. He leads clinical research in the Myeloproliferative Disorders Program and directs the Adult Leukemia Program. Dr. Mascarenhas assesses rationale-based innovative therapeutics for patients with MPNs and AML as a clinical investigator in malignant hematology with a focus on translational research involving myeloproliferative neoplasms (MPNs) and their development to acute myeloid leukemia (AML). In this video Dr. Mascarenhas discusses the Oral ASH…

Professor Guy Young, MD, Director, Hemostasis, and Thrombosis Center at Children’s Hospital Los Angeles, Professor of Pediatrics at the Keck School of Medicine of USC speaks about the ASH 2021 Abstract 4 Efficacy and Safety of Fitusiran Prophylaxis, an siRNA Therapeutic, in a Multicenter Phase 3 Study (ATLAS-INH) in People with Hemophilia A or B, with Inhibitors (PwHI).Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper150273.htmlIntroduction:Hemophilia A and B are rare bleeding disorders defined by inefficient clot formation due to thrombin production impairment caused by FVIII or FIX deficiency, respectively. Fitusiran is an experimental siRNA therapy targeting antithrombin that is delivered subcutaneously (SC) to restore thrombin…

Dr. John Mascarenhas is a member of The Tisch Cancer Institute and a professor of medicine at Mount Sinai’s Icahn School of Medicine. He is also the director of the Center of Excellence for Blood Cancers and Myeloid Disorders. He leads clinical research in the Myeloproliferative Disorders Program and directs the Adult Leukemia Program. Dr. Mascarenhas assesses rationale-based innovative therapeutics for patients with MPNs and AML as a clinical investigator in malignant hematology with a focus on translational research involving myeloproliferative neoplasms (MPNs) and their development to acute myeloid leukemia (AML). In this video Dr. Mascarenhas discusses the Oral ASH…

Professor Guy Young, MD, Director, Hemostasis, and Thrombosis Center at Children’s Hospital Los Angeles, Professor of Pediatrics at the Keck School of Medicine of USC speaks about the ASH 2021 Abstract 4 Efficacy and Safety of Fitusiran Prophylaxis, an siRNA Therapeutic, in a Multicenter Phase 3 Study (ATLAS-INH) in People with Hemophilia A or B, with Inhibitors (PwHI).Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper150273.htmlIntroduction:Hemophilia A and B are rare bleeding disorders defined by inefficient clot formation due to thrombin production impairment caused by FVIII or FIX deficiency, respectively. Fitusiran is an experimental siRNA therapy targeting antithrombin that is delivered subcutaneously (SC) to restore thrombin…

Amy Xu, MD, Ph.D. from Memorial Sloan Kettering Cancer Center speaks about the SABCS 2021 Presentation – Oligo-progressive disease. Treating locally more than systemically.

Amy Xu, MD, Ph.D. from Memorial Sloan Kettering Cancer Center speaks about the SABCS 2021 Presentation – Oligo-progressive disease. Treating locally more than systemically.

Mikkael A. Sekeres, MD from Sylvester Comprehensive Cancer Center, University of Miami speaks about the ASH 2021 Abstract – 242 Pevonedistat (PEV) + Azacitidine (AZA) Versus AZA Alone As First-Line Treatment for Patients with Higher-Risk Myelodysplastic Syndromes (MDS)/Chronic Myelomonocytic Leukemia (CMML) or Acute Myeloid Leukemia (AML) with 20–30% Marrow Blasts: The Randomized Phase 3 PANTHER Trial (NCT03268954).Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper146154.htmlBackground:Single-agent hypomethylating agent (HMA) therapy is often used in older patients with higher-risk MDS/CMML or AML with 20–30 percent marrow blasts. The median response duration and survival for these individuals is poor, and many MDS patients progress to secondary AML, which has…

Mikkael A. Sekeres, MD from Sylvester Comprehensive Cancer Center, University of Miami speaks about the ASH 2021 Abstract – 242 Pevonedistat (PEV) + Azacitidine (AZA) Versus AZA Alone As First-Line Treatment for Patients with Higher-Risk Myelodysplastic Syndromes (MDS)/Chronic Myelomonocytic Leukemia (CMML) or Acute Myeloid Leukemia (AML) with 20–30% Marrow Blasts: The Randomized Phase 3 PANTHER Trial (NCT03268954).Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper146154.htmlBackground:Single-agent hypomethylating agent (HMA) therapy is often used in older patients with higher-risk MDS/CMML or AML with 20–30 percent marrow blasts. The median response duration and survival for these individuals is poor, and many MDS patients progress to secondary AML, which has…

Pedram Razavi, MD, Ph.D. from Memorial Sloan Kettering Cancer Center speaks about SABCS 2021 Presentation – Challenges in early detection – screening and MRD.

Pedram Razavi, MD, Ph.D. from Memorial Sloan Kettering Cancer Center speaks about SABCS 2021 Presentation – Challenges in early detection – screening and MRD.

Dr. Jeffrey Zonder, MD is a Hematology Specialist in Detroit, Michigan, with over 26 years of expertise. In 1995, he received his medical degree from Wayne State University School Of Medicine. DMC Hutzel Women’s Hospital is where he works. In this video Dr. Zonder discusses the REGN5458 (BCMAXCD3) Phase 1 Data. https://ash.confex.com/ash/2021/webprogram/Paper144921.html REGN5458 is a bispecific antibody designed to bind to BCMA on multiple myeloma cells and the CD3 receptor on T-cells in order to bridge them together and activate T-cells to kill the cancer cells. It is now being evaluated as part of the potentially registrational Phase 2 component…

Steven W. Pipe, MD from the Department of Pediatrics and Pathology, University of Michigan speaks about 972 Relationship between Endogenous, Transgene FVIII Expression and Bleeding Events Following Valoctocogene Roxaparvovec Gene Transfer for Severe Hemophilia A: A Post-Hoc Analysis of the GENEr8-1 Phase 3 Trial.Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper144508.htmla brief introduction -The adeno-associated virus gene therapy valoctocogene roxaparvovec (AAV5-hFVIII-SQ) delivers a B-domain deleted factor VIII (FVIII) cDNA to hepatocytes. In 134 men with severe hemophilia A (HA), the open-label, single-arm, multicenter phase 3 GENEr8-1 study (NCT03370913) found that valoctocogene roxaparvovec reduced annualized treated bleeding rate (ABR) by 83.8 percent and was superior to…

Steven W. Pipe, MD from the Department of Pediatrics and Pathology, University of Michigan speaks about 972 Relationship between Endogenous, Transgene FVIII Expression and Bleeding Events Following Valoctocogene Roxaparvovec Gene Transfer for Severe Hemophilia A: A Post-Hoc Analysis of the GENEr8-1 Phase 3 Trial.Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper144508.htmla brief introduction -The adeno-associated virus gene therapy valoctocogene roxaparvovec (AAV5-hFVIII-SQ) delivers a B-domain deleted factor VIII (FVIII) cDNA to hepatocytes. In 134 men with severe hemophilia A (HA), the open-label, single-arm, multicenter phase 3 GENEr8-1 study (NCT03370913) found that valoctocogene roxaparvovec reduced annualized treated bleeding rate (ABR) by 83.8 percent and was superior to…

John Mascarenhas, MD, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai speaks about the ASH 2021 Abstract – 1503 A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat Versus Best Available Therapy (BAT) in Patients with Intermediate-2 (Int-2) or High-Risk Myelofibrosis (MF) Refractory to Janus Kinase Inhibitor (JAKi).Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper148931.htmlMyeloproliferative neoplasm (MF) is a life-threatening myeloproliferative tumor. Only the JAKi inhibitors ruxolitinib and fedratinib have been approved by the FDA as treatments for MF. Despite the benefits reported with ruxolitinib in the frontline setting, a high proportion of patients (pts) discontinue treatment (Abdelrahman 2015), and the median overall…

John Mascarenhas, MD, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai speaks about the ASH 2021 Abstract – 1503 A Randomized Open-Label, Phase 3 Study to Evaluate Imetelstat Versus Best Available Therapy (BAT) in Patients with Intermediate-2 (Int-2) or High-Risk Myelofibrosis (MF) Refractory to Janus Kinase Inhibitor (JAKi).Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper148931.htmlMyeloproliferative neoplasm (MF) is a life-threatening myeloproliferative tumor. Only the JAKi inhibitors ruxolitinib and fedratinib have been approved by the FDA as treatments for MF. Despite the benefits reported with ruxolitinib in the frontline setting, a high proportion of patients (pts) discontinue treatment (Abdelrahman 2015), and the median overall…

Shyamala Maheswaran, Ph.D. from Massachusetts General Hospital speaks about the SABCS Presentation – Single Cell Analysis Of Circulating Tumor Cells.

Shyamala Maheswaran, Ph.D. from Massachusetts General Hospital speaks about the SABCS Presentation – Single Cell Analysis Of Circulating Tumor Cells.

Shaji Kumar, MD, Division of Hematology, Department of Internal Medicine, Mayo Clinic speaks about the ASH 2021 Abstract – 84 Final Overall Survival Results from BELLINI, a Phase 3 Study of Venetoclax or Placebo in Combination with Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma.Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper145757.htmlBackground:Multiple myeloma (MM) is a malignancy characterized by terminally differentiated plasma cells that produce high levels of antiapoptotic proteins such as BCL­­­-2. Venetoclax (Ven), an oral BCL-2 inhibitor that promotes apoptosis in MM cells, showed promise efficacy when coupled with bortezomib and dexamethasone in patients with relapsed/refractory MM (RRMM; Moreau et al. Blood. 2017;130:2392-2400). The…

Shaji Kumar, MD, Division of Hematology, Department of Internal Medicine, Mayo Clinic speaks about the ASH 2021 Abstract – 84 Final Overall Survival Results from BELLINI, a Phase 3 Study of Venetoclax or Placebo in Combination with Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma.Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper145757.htmlBackground:Multiple myeloma (MM) is a malignancy characterized by terminally differentiated plasma cells that produce high levels of antiapoptotic proteins such as BCL­­­-2. Venetoclax (Ven), an oral BCL-2 inhibitor that promotes apoptosis in MM cells, showed promise efficacy when coupled with bortezomib and dexamethasone in patients with relapsed/refractory MM (RRMM; Moreau et al. Blood. 2017;130:2392-2400). The…

Dr. Raymond L. Comenzo is a Tufts Medical Center-affiliated oncologist in Boston, Massachusetts. He graduated from Boston University School of Medicine and has been practicing medicine for almost 20 years. In this video Dr. Comenzo discusses the Subcutaneous Daratumumab with Bortezomib, Cyclophosphamide, and Dexamethasone in Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: 18-Month Analysis of the Phase 3 ANDROMEDA StudyLink to Abstract-https://ash.confex.com/ash/2021/webprogram/Paper146820.htmlIntroduction: Light chain (AL) amyloidosis is a plasma cell disease in which insoluble amyloid fibrils develop in tissues, causing organ failure and death. The ANDROMEDA trial (NCT03201965) found that adding SC daratumumab to the standard-of-care combination of bortezomib,…

Morie A Gertz, MD, MACP from the Division of Hematology, Department of Internal Medicine, Mayo Clinic speaks about the ASH 2021 Abstract – 2754 Birtamimab in Patients with Mayo Stage IV AL Amyloidosis: Rationale for Confirmatory Affirm-AL Phase 3 Study Design.Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper146076.htmlBackground:Light chain (AL) amyloidosis is a rare, deadly hematologic condition characterized by misfolded AL protein produced by plasma cells, culminating in amyloid deposits in tissues and organs, causing organ malfunction and failure. Birtamimab is an experimental monoclonal antibody that neutralizes circulating soluble amyloid and deposited insoluble amyloid, allowing amyloid deposits to be phagocytized and cleared. The global phase…

Morie A Gertz, MD, MACP from the Division of Hematology, Department of Internal Medicine, Mayo Clinic speaks about the ASH 2021 Abstract – 2754 Birtamimab in Patients with Mayo Stage IV AL Amyloidosis: Rationale for Confirmatory Affirm-AL Phase 3 Study Design.Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper146076.htmlBackground:Light chain (AL) amyloidosis is a rare, deadly hematologic condition characterized by misfolded AL protein produced by plasma cells, culminating in amyloid deposits in tissues and organs, causing organ malfunction and failure. Birtamimab is an experimental monoclonal antibody that neutralizes circulating soluble amyloid and deposited insoluble amyloid, allowing amyloid deposits to be phagocytized and cleared. The global phase…

Dr. Med. Prof. Martin Dreyling, PhD, Department of Medicine III, LMU Hospital speaks about ASH 2021 Abstract – 383 R-High Dose Cytarabine/Dexamethasone (R-HAD) Plus Bortezomib Is Superior to R-HAD Only in Relapsed Mantle Cell Lymphoma: A Randomized Phase 3 Trial of the European MCL Network.Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper148585.htmlBackground:Relapsed mantle cell lymphoma (MCL) has an aggressive clinical history and only achieves a short-term remission after immunochemotherapy. The addition of high-dose cytarabine to a CHOP-like regimen resulted in significantly longer time to treatment failure (TTF) in younger patients (Hermine et al, Lancet 2016), whereas the addition of bortezomib to a CHOP-like regimen resulted…

Dr. Med. Prof. Martin Dreyling, PhD, Department of Medicine III, LMU Hospital speaks about ASH 2021 Abstract – 383 R-High Dose Cytarabine/Dexamethasone (R-HAD) Plus Bortezomib Is Superior to R-HAD Only in Relapsed Mantle Cell Lymphoma: A Randomized Phase 3 Trial of the European MCL Network.Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper148585.htmlBackground:Relapsed mantle cell lymphoma (MCL) has an aggressive clinical history and only achieves a short-term remission after immunochemotherapy. The addition of high-dose cytarabine to a CHOP-like regimen resulted in significantly longer time to treatment failure (TTF) in younger patients (Hermine et al, Lancet 2016), whereas the addition of bortezomib to a CHOP-like regimen resulted…

Yael Cohen, MD from Tel-Aviv Sourasky (Ichilov) Medical Center, and Sackler School of Medicine, Tel Aviv University speaks about the ASH 2021 Abstract – 3866 Efficacy and Safety of Ciltacabtagene Autoleucel (Cilta-cel), a B-Cell Maturation Antigen (BCMA)–Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy, in Lenalidomide-Refractory Patients with Progressive Multiple Myeloma after 1–3 Prior Lines of Therapy: Updated Results from CARTITUDE-2.Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper146072.htmlIntroduction:Patients with progressive multiple myeloma (MM) who are refractory to lenalidomide have numerous therapy choices, however most pts relapse quickly after getting salvage medication. In the phase 1b/2 CARTITUDE-1 research, Cilta-cel, a CAR-T treatment expressing two BCMA-targeting, single-domain antibodies,…

Dr. Raymond L. Comenzo is a Tufts Medical Center-affiliated oncologist in Boston, Massachusetts. He graduated from Boston University School of Medicine and has been practicing medicine for almost 20 years. In this video Dr. Comenzo discusses the Subcutaneous Daratumumab with Bortezomib, Cyclophosphamide, and Dexamethasone in Patients with Newly Diagnosed Light Chain (AL) Amyloidosis: 18-Month Analysis of the Phase 3 ANDROMEDA Study.Link to Abstract- https://ash.confex.com/ash/2021/webprogram/Paper146820.htmlIntroduction: Light chain (AL) amyloidosis is a plasma cell disease in which insoluble amyloid fibrils develop in tissues, causing organ failure and death. The ANDROMEDA trial (NCT03201965) found that adding SC daratumumab to the standard-of-care combination of…

Yael Cohen, MD from Tel-Aviv Sourasky (Ichilov) Medical Center, and Sackler School of Medicine, Tel Aviv University speaks about the ASH 2021 Abstract – 3866 Efficacy and Safety of Ciltacabtagene Autoleucel (Cilta-cel), a B-Cell Maturation Antigen (BCMA)–Directed Chimeric Antigen Receptor (CAR) T-Cell Therapy, in Lenalidomide-Refractory Patients with Progressive Multiple Myeloma after 1–3 Prior Lines of Therapy: Updated Results from CARTITUDE-2.Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper146072.htmlIntroduction:Patients with progressive multiple myeloma (MM) who are refractory to lenalidomide have numerous therapy choices, however most pts relapse quickly after getting salvage medication. In the phase 1b/2 CARTITUDE-1 research, Cilta-cel, a CAR-T treatment expressing two BCMA-targeting, single-domain antibodies,…

Professor Andrew Wei is a haematologist at the Alfred Hospital and a Victorian Cancer Agency Research Fellow. Andrew has dual appointments at the Alfred Hospital and Monash University, where he does clinical and translational AML research. In this video Professor Wei discusses the Long-Term Overall Survival (OS) with Oral Azacitidine (Oral-AZA) in Patients with Acute Myeloid Leukemia (AML) in First Remission after Intensive Chemotherapy (IC): Updated Results from the Phase 3 QUAZAR AML-001 Trial. Link to Abstract-https://ash.confex.com/ash/2021/webprogram/Paper147501.htmlBACKGROUND: While many older patients (pts) with AML achieve complete remission (CR) with IC therapy, 80% will recur, and overall survival (OS) is dismal.…

Professor Andrew Wei is a haematologist at the Alfred Hospital and a Victorian Cancer Agency Research Fellow. Andrew has dual appointments at the Alfred Hospital and Monash University, where he does clinical and translational AML research. In this video Professor Wei discusses the Long-Term Overall Survival (OS) with Oral Azacitidine (Oral-AZA) in Patients with Acute Myeloid Leukemia (AML) in First Remission after Intensive Chemotherapy (IC): Updated Results from the Phase 3 QUAZAR AML-001 Trial. Link to Abstract-https://ash.confex.com/ash/2021/webprogram/Paper147501.htmlBACKGROUND: While many older patients (pts) with AML achieve complete remission (CR) with IC therapy, 80% will recur, and overall survival (OS) is dismal.…

Elizabeth Lihua Budde, MD, Ph.D. Associate Professor, Division of Lymphoma, Department of Hematology & Hematopoietic Cell Transplantation at the City of Hope speaks about the ASH 2021 Abstract 127 Mosunetuzumab Monotherapy Is an Effective and Well-Tolerated Treatment Option for Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) Who Have Received ≥2 Prior Lines of Therapy: Pivotal Results from a Phase I/II Study.Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper145872.htmlBackground:With each course of conventional therapy, FL is linked to more relapses and shorter progression-free intervals. Due to refractory disease, later-line therapies may be less successful. Mosunetuzumab (Mosun) is a bispecific CD20xCD3 antibody (Ab) that drives T lymphocytes…

Elizabeth Lihua Budde, MD, Ph.D. Associate Professor, Division of Lymphoma, Department of Hematology and; Hematopoietic Cell Transplantation at the City of Hope speaks about the ASH 2021 Abstract 127 Mosunetuzumab Monotherapy Is an Effective and Well-Tolerated Treatment Option for Patients with Relapsed/Refractory (R/R) Follicular Lymphoma (FL) Who Have Received ≥2 Prior Lines of Therapy: Pivotal Results from a Phase I/II Study.Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper145872.htmlBackground:With each course of conventional therapy, FL is linked to more relapses and shorter progression-free intervals. Due to refractory disease, later-line therapies may be less successful. Mosunetuzumab (Mosun) is a bispecific CD20xCD3 antibody (Ab) that drives T lymphocytes…

Dr. Verstovsek is a hematologist-oncologist at MD Anderson and the United Energy Resources, Inc., Professor of Medicine. Dr. Verstovsek is a world-renowned expert in myeloproliferative neoplasms (MPN) and the founder/director of the world’s largest MPN Clinical Research Center. Dr. Verstovsek has received international praise for his role in the development of ground-breaking MPN therapies. He oversaw more than 60 early/advanced phase clinical trials of innovative MPN medications, including ruxolitinib, the only FDA-approved prescription for myelofibrosis (MF) until 2019, and polycythemia vera’s second-line treatment. In this video Dr. Verstovsek discuses the Phase 2 MANIFEST Study evaluating the potential of pelabresib in…

Dr. Verstovsek is a hematologist-oncologist at MD Anderson and the United Energy Resources, Inc., Professor of Medicine. Dr. Verstovsek is a world-renowned expert in myeloproliferative neoplasms (MPN) and the founder/director of the world’s largest MPN Clinical Research Center. Dr. Verstovsek has received international praise for his role in the development of ground-breaking MPN therapies. He oversaw more than 60 early/advanced phase clinical trials of innovative MPN medications, including ruxolitinib, the only FDA-approved prescription for myelofibrosis (MF) until 2019, and polycythemia vera’s second-line treatment. In this video Dr. Verstovsek discuses the Phase 2 MANIFEST Study evaluating the potential of pelabresib in…

Dr. Jeffrey Zonder, MD is a Hematology Specialist in Detroit, Michigan, with over 26 years of expertise. In 1995, he received his medical degree from Wayne State University School Of Medicine. DMC Hutzel Women’s Hospital is where he works. In this video Dr. Zonder discusses the REGN5458 (BCMAXCD3) Phase 1 Data. https://ash.confex.com/ash/2021/webprogram/Paper144921.html REGN5458 is a bispecific antibody designed to bind to BCMA on multiple myeloma cells and the CD3 receptor on T-cells in order to bridge them together and activate T-cells to kill the cancer cells. It is now being evaluated as part of the potentially registrational Phase 2 component…

Dr. Francesco Passamonti is the Director of the University Hospital of Varese’s Hematology Division. He earned his medical degree from the University of Pavia and went on to become a hematology expert. He served as a hematologist at the Policlinico San Matteo in Pavia, Italy, and as an assistant professor of hematology at the University of Pavia. He serves on the International Working Group on Myeloproliferative Research and Treatment (IWGMRT) Board of Directors, as well as the European LeukemiaNet Work Package 9 for MPN and the GIMEMA Working Party for MPN. He has published over 170 publications on MPN and…

Dr. Francesco Passamonti is the Director of the University Hospital of Varese’s Hematology Division. He earned his medical degree from the University of Pavia and went on to become a hematology expert. He served as a hematologist at the Policlinico San Matteo in Pavia, Italy, and as an assistant professor of hematology at the University of Pavia. He serves on the International Working Group on Myeloproliferative Research and Treatment (IWGMRT) Board of Directors, as well as the European LeukemiaNet Work Package 9 for MPN and the GIMEMA Working Party for MPN. He has published over 170 publications on MPN and…

Dr. Rifkin is a board-certified medical oncologist and hematologist who treats blood malignancies and diseases, both malignant and benign. He specializes in coagulation diseases, multiple myeloma, and biosimilars at the advanced subspecialty level. Dr. Rifkin follows the National Comprehensive Cancer Network’s (NCCN) standards and performs evidence-based care. In this video Dr. Rifkin discusses the Real-World Treatment Patterns and Clinical, Economic, and Humanistic Burden in Triple-Class Refractory Multiple Myeloma: Analysis of the Connect® Multiple Myeloma (MM) Disease Registry.Introduction: Treatment resistance is a problem that most MM patients (pts) will face at some point during their illness. Patient outcomes and health-related quality of…

Dr. Rifkin is a board-certified medical oncologist and hematologist who treats blood malignancies and diseases, both malignant and benign. He specializes in coagulation diseases, multiple myeloma, and biosimilars at the advanced subspecialty level. Dr. Rifkin follows the National Comprehensive Cancer Network’s (NCCN) standards and performs evidence-based care. In this video Dr. Rifkin discusses the Real-World Treatment Patterns and Clinical, Economic, and Humanistic Burden in Triple-Class Refractory Multiple Myeloma: Analysis of the Connect® Multiple Myeloma (MM) Disease Registry.Introduction: Treatment resistance is a problem that most MM patients (pts) will face at some point during their illness. Patient outcomes and health-related quality of…

Dr. Eunice Wang is the Director of the Roswell Park Comprehensive Cancer Center’s Leukemia Service. Dr. Wang joined the Roswell Park faculty in 2003 and was assigned to the Department of Medicine’s Leukemia Service. She received her medical degree from the University of Southern California’s Keck School of Medicine and finished her residency in Internal Medicine at Yale-New Haven Hospital, Yale University, New Haven, CT, in 1999. She did a clinical hematology-oncology and research residency at Memorial Sloan Kettering Cancer Center in New York, NY, from 1999 to 2003. In this video Dr. Wang discusses the Open-Label, Randomized Study of…

Dr. Eunice Wang is the Director of the Roswell Park Comprehensive Cancer Center’s Leukemia Service. Dr. Wang joined the Roswell Park faculty in 2003 and was assigned to the Department of Medicine’s Leukemia Service. She received her medical degree from the University of Southern California’s Keck School of Medicine and finished her residency in Internal Medicine at Yale-New Haven Hospital, Yale University, New Haven, CT, in 1999. She did a clinical hematology-oncology and research residency at Memorial Sloan Kettering Cancer Center in New York, NY, from 1999 to 2003. In this video Dr. Wang discusses the Open-Label, Randomized Study of…

James H. Essell, MD, is a renowned expert on blood and marrow stem cell transplants and is a medical oncologist, hematologist, and blood and marrow transplant specialist. Dr. Essell is a national expert and author who directs The US Oncology Network’s cellular treatment program. Dr. Essell is the national principle investigator for The US Oncology Network’s CAR-T clinical trials and a principal investigator for blood cancer clinical trials at OHC. He is also the Medical Director of Mercy Health Cincinnati’s Cancer and Cellular Therapy Center at The Jewish Hospital. In this video Dr. Essell discusses the Results from a Phase…

James H. Essell, MD, is a renowned expert on blood and marrow stem cell transplants and is a medical oncologist, hematologist, and blood and marrow transplant specialist. Dr. Essell is a national expert and author who directs The US Oncology Network’s cellular treatment program. Dr. Essell is the national principle investigator for The US Oncology Network’s CAR-T clinical trials and a principal investigator for blood cancer clinical trials at OHC. He is also the Medical Director of Mercy Health Cincinnati’s Cancer and Cellular Therapy Center at The Jewish Hospital. In this video Dr. Essell discusses the Results from a Phase…

Professor Peter Schmid, MD, Ph.D. from Bart’s Cancer Institute, Queen Mary University of London speaks about SABCS 2021 Review of the Year – Advanced Breast Cancer.

Professor Peter Schmid, MD, Ph.D. from Bart’s Cancer Institute, Queen Mary University of London speaks about SABCS 2021 Review of the Year – Advanced Breast Cancer.

Professor Patricia Ganz, MD, Director of Cancer Prevention and Control Research at the Jonsson Comprehensive Cancer Center speaks about the SABCS 2021 Abstract – GS4-09 Quality of life results from OlympiA: A phase III, multicenter, randomized, placebo-controlled trial of adjuvant olaparib after (neo)-adjuvant chemotherapy in patients with germline BRCA1/2 mutations and high-risk HER-2 negative early breast cancer.Link to Abstract:https://www.nejm.org/doi/full/10.1056/NEJMoa2105215Link to Clinical Trials.gov:https://clinicaltrials.gov/ct2/show/NCT02032823a summary -BACKGROUND:By synthetic lethality, poly(adenosine diphosphate–ribose) polymerase inhibitors target tumors with deficiencies in homologous recombination repair. In individuals with BRCA1 or BRCA2 germline mutation–associated early breast cancer, new medicines are needed to prevent recurrence.METHODS:Patients with human epidermal growth…

Professor Patricia Ganz, MD, Director of Cancer Prevention and Control Research at the Jonsson Comprehensive Cancer Center speaks about the SABCS 2021 Abstract – GS4-09 Quality of life results from OlympiA: A phase III, multicenter, randomized, placebo-controlled trial of adjuvant olaparib after (neo)-adjuvant chemotherapy in patients with germline BRCA1/2 mutations and high-risk HER-2 negative early breast cancer.Link to Abstract:https://www.nejm.org/doi/full/10.1056/NEJMoa2105215Link to Clinical Trials.gov:https://clinicaltrials.gov/ct2/show/NCT02032823a summary -BACKGROUND:By synthetic lethality, poly(adenosine diphosphate–ribose) polymerase inhibitors target tumors with deficiencies in homologous recombination repair. In individuals with BRCA1 or BRCA2 germline mutation–associated early breast cancer, new medicines are needed to prevent recurrence.METHODS:Patients with human epidermal growth…

Stephan A. Grupp, MD, Ph.D., Cell Therapy and Transplant Section, The Children’s Hospital of Philadelphia speaks about the ASH 2021 Abstract – 749 A Phase 3, Randomized, Adaptive Study of Defibrotide (DF) Vs Best Supportive Care (BSC) for the Prevention of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS) in Patients (pts) Undergoing Hematopoietic Cell Transplantation (HCT): Preliminary Results.Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper147284.htmlIntroduction:A potentially life-threatening consequence of HCT is hepatic VOD/SOS. If left untreated, VOD/SOS with multiorgan dysfunction/multiorgan failure (MOD/MOF) has a death risk of >80%. In the US, DF is approved for VOD/SOS with renal or pulmonary failure after HCT, while in the…

Stephan A. Grupp, MD, Ph.D., Cell Therapy and Transplant Section, The Children’s Hospital of Philadelphia speaks about the ASH 2021 Abstract – 749 A Phase 3, Randomized, Adaptive Study of Defibrotide (DF) Vs Best Supportive Care (BSC) for the Prevention of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS) in Patients (pts) Undergoing Hematopoietic Cell Transplantation (HCT): Preliminary Results.Link to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper147284.htmlIntroduction:A potentially life-threatening consequence of HCT is hepatic VOD/SOS. If left untreated, VOD/SOS with multiorgan dysfunction/multiorgan failure (MOD/MOF) has a death risk of >80%. In the US, DF is approved for VOD/SOS with renal or pulmonary failure after HCT, while in the…

Pamela J. Sung, MD from the Department of Medicine, Roswell Park Comprehensive Cancer Center speaks about ASH 2021 Abstract – 785 FLT3 Inhibition Downregulates EZH2 in AML and Promotes Myeloid Differentiation.Link to Abstract -https://ash.confex.com/ash/2021/webprogram/Paper147313.htmlFms-like tyrosine kinase 3 (FLT3-ITD) internal tandem duplication mutations are common in AML and are associated with a poor prognosis. In relapsed AML, FLT3 inhibitors (FLT3i) like gilteritinib are effective. In around half of the patients who receive FLT3i, myeloid differentiation of the FLT3-ITD clone occurs. It’s unclear how FLT3i causes this response in a subgroup of people.Animal models have not previously displayed the FLT3i-induced differentiation response…

Pamela J. Sung, MD from the Department of Medicine, Roswell Park Comprehensive Cancer Center speaks about ASH 2021 Abstract – 785 FLT3 Inhibition Downregulates EZH2 in AML and Promotes Myeloid Differentiation.Link to Abstract -https://ash.confex.com/ash/2021/webprogram/Paper147313.htmlFms-like tyrosine kinase 3 (FLT3-ITD) internal tandem duplication mutations are common in AML and are associated with a poor prognosis. In relapsed AML, FLT3 inhibitors (FLT3i) like gilteritinib are effective. In around half of the patients who receive FLT3i, myeloid differentiation of the FLT3-ITD clone occurs. It’s unclear how FLT3i causes this response in a subgroup of people.Animal models have not previously displayed the FLT3i-induced differentiation response…

Mara-Victoria Mateos earned her medical degree from the University of Valladolid in Spain and finished her hematological residency at the Salamanca University Hospital, where she also earned her doctorate . Dr. Mateos is currently an Associate Professor of Psychology. In this video Dr. Mateos discusses the 550 Ciltacabtagene Autoleucel for Triple-Class Exposed Multiple MyelomaLink to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper146200.htmlAbstract:Patients with relapsed and refractory multiple myeloma (RRMM) who have been exposed to immunomodulatory medicines (IMiDs), proteasome inhibitors (PIs), and anti-CD38 monoclonal antibodies (MoABs) in the triple class have a poor prognosis and a large unmet medical need. Ciltacabtagene autoleucel (cilta-cel) is a chimeric antigen…

Mara-Victoria Mateos earned her medical degree from the University of Valladolid in Spain and finished her hematological residency at the Salamanca University Hospital, where she also earned her doctorate . Dr. Mateos is currently an Associate Professor of Psychology. In this video Dr. Mateos discusses the 550 Ciltacabtagene Autoleucel for Triple-Class Exposed Multiple MyelomaLink to Abstract:https://ash.confex.com/ash/2021/webprogram/Paper146200.htmlAbstract:Patients with relapsed and refractory multiple myeloma (RRMM) who have been exposed to immunomodulatory medicines (IMiDs), proteasome inhibitors (PIs), and anti-CD38 monoclonal antibodies (MoABs) in the triple class have a poor prognosis and a large unmet medical need. Ciltacabtagene autoleucel (cilta-cel) is a chimeric antigen…

Dr. Heather Han is a medical oncologist and the Research Director of the Moffitt Cancer Center’s Department of Breast Oncology. She is committed to finding a cure for the millions of women whose lives have been impacted by a breast cancer diagnosis. In this video Dr. Han speaks on the OT1-16-01 A multicenter phase II study of vaccines to prevent recurrence in patients with HER-2 positive breast cancer.Abstract-The maximum limit of the Disclosure Block has been reached.Background: In patients with early-stage TNBC, KEYNOTE-522 (NCT03036488) is a phase 3 study comparing neoadjuvant pembro + chemo to placebo Plus chemo, followed by…

Dr. Heather Han is a medical oncologist and the Research Director of the Moffitt Cancer Center’s Department of Breast Oncology. She is committed to finding a cure for the millions of women whose lives have been impacted by a breast cancer diagnosis. In this video Dr. Han speaks on the OT1-16-01 A multicenter phase II study of vaccines to prevent recurrence in patients with HER-2 positive breast cancer.Abstract-The maximum limit of the Disclosure Block has been reached.Background: In patients with early-stage TNBC, KEYNOTE-522 (NCT03036488) is a phase 3 study comparing neoadjuvant pembro + chemo to placebo Plus chemo, followed by…

Douglas W. Blayney, MD, is a professor of medicine (oncology) at Stanford University and the former Medical Director of Stanford Cancer Center. He specializes in breast cancer treatment. He is particularly concerned about the quality and value of cancer care. In this video Dr. Blayney discusses the Phase 3 PROTECTIVE-2 TRIAL.Plunabulin significantly reduces bone pain in breast cancer patients (pts) treated with TAC (docetaxel, doxorubicin, cyclophosphamide) and pegfilgrastim, according to mechanistic evidence (Peg)Publication Number: P5-18-01Patients who received both pegfilgrastim and plinabulin experienced less bone discomfort than those who received only pegfilgrastim (p=0.03).Planabulin treatment may reduce the requirement for compensatory hematopoiesis…

Douglas W. Blayney, MD, is a professor of medicine (oncology) at Stanford University and the former Medical Director of Stanford Cancer Center. He specializes in breast cancer treatment. He is particularly concerned about the quality and value of cancer care. In this video Dr. Blayney discusses the Phase 3 PROTECTIVE-2 TRIAL.Plunabulin significantly reduces bone pain in breast cancer patients (pts) treated with TAC (docetaxel, doxorubicin, cyclophosphamide) and pegfilgrastim, according to mechanistic evidence (Peg)Publication Number: P5-18-01Patients who received both pegfilgrastim and plinabulin experienced less bone discomfort than those who received only pegfilgrastim (p=0.03).Planabulin treatment may reduce the requirement for compensatory hematopoiesis…

Irene Wapnir, MD from Stanford University School of Medicine speaks about SABCS Abstract OT1-09-01 A randomized study comparing surgical excision versus NeOadjuvant Radiotherapy followed by delayed surgical excision of Ductal carcinoma In Situ (NORDIS).Link to Trial:https://clinicaltrials.gov/ct2/show/NCT03909282Introduction:In individuals with ductal carcinoma in situ, lumpectomy plus breast radiation (RT) provide satisfactory long-term disease management (DCIS). These therapies were found to prevent invasive ipsilateral breast tumor recurrences by 52 percent when compared to lumpectomy alone in a combined analysis of the NSABP B17/24 trials. Because RT has been used as an adjuvant to surgery for so long, nothing is known about its effects…

Irene Wapnir, MD from Stanford University School of Medicine speaks about SABCS Abstract OT1-09-01 A randomized study comparing surgical excision versus NeOadjuvant Radiotherapy followed by delayed surgical excision of Ductal carcinoma In Situ (NORDIS).Link to Trial:https://clinicaltrials.gov/ct2/show/NCT03909282Introduction:In individuals with ductal carcinoma in situ, lumpectomy plus breast radiation (RT) provide satisfactory long-term disease management (DCIS). These therapies were found to prevent invasive ipsilateral breast tumor recurrences by 52 percent when compared to lumpectomy alone in a combined analysis of the NSABP B17/24 trials. Because RT has been used as an adjuvant to surgery for so long, nothing is known about its effects…

Charles E. Geyer, Jr., MD, FACP, Deputy Director of the Houston Methodist Cancer Center, and Study Co-Chair speaks about SABCS Abstract – OT1-02-03 Trastuzumab deruxtecan (T-DXd; DS-8201) vs trastuzumab emtansine (T-DM1) in high-risk patients with HER2-positive, residual invasive early breast cancer after neoadjuvant therapy: A randomized, phase 3 trial (DESTINY-Breast05).Link to Abstract:https://www.sabcs.org/Portals/SABCS2016/2021%20SABCS/SABCS%202021%20Abstracts.pdf?ver=2021-11-19-080202-743&utm_source=Jaguar+Health%2C+Inc.+Investor+Contacts&utm_campaign=8777ae34f6-Earnings+Call+111417_COPY_01&utm_medium=email&utm_term=0_4612a17168-8777ae34f6-610272854&mc_cid=8777ae34f6&mc_eid=3a5efd49f4Background:Preoperative chemotherapy with trastuzumab and pertuzumab is the primary treatment for HER2-positive, invasive, early breast cancer patients (pts) (BC). Patients who have undergone such treatment but still have invasive disease in the breast or lymph nodes at surgery are at a higher risk of disease recurrence or death than…

Charles E. Geyer, Jr., MD, FACP, Deputy Director of the Houston Methodist Cancer Center, and Study Co-Chair speaks about SABCS Abstract – OT1-02-03 Trastuzumab deruxtecan (T-DXd; DS-8201) vs trastuzumab emtansine (T-DM1) in high-risk patients with HER2-positive, residual invasive early breast cancer after neoadjuvant therapy: A randomized, phase 3 trial (DESTINY-Breast05).Link to Abstract:https://www.sabcs.org/Portals/SABCS2016/2021%20SABCS/SABCS%202021%20Abstracts.pdf?ver=2021-11-19-080202-743&utm_source=Jaguar+Health%2C+Inc.+Investor+Contacts&utm_campaign=8777ae34f6-Earnings+Call+111417_COPY_01&utm_medium=email&utm_term=0_4612a17168-8777ae34f6-610272854&mc_cid=8777ae34f6&mc_eid=3a5efd49f4Background:Preoperative chemotherapy with trastuzumab and pertuzumab is the primary treatment for HER2-positive, invasive, early breast cancer patients (pts) (BC). Patients who have undergone such treatment but still have invasive disease in the breast or lymph nodes at surgery are at a higher risk of disease recurrence or death than…

Meredith M. Regan, ScD, Associate Professor of Medicine, Dana-Farber Cancer Institute/Harvard Medical School speaks about the SABCS 2021 Abstract – GS2-05 Randomized comparison of adjuvant aromatase inhibitor exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC): update of the combined TEXT and SOFT trials.Link to Abstract:https://www.sabcs.org/Portals/SABCS2016/2021%20SABCS/SABCS21_embargoedAbstracts_111921.pdf?ver=2021-11-19-141323-927Background:After 9 years of median follow-up (MFU), the updated combined SOFT+TEXT analysis demonstrated that adjuvant E+OFS vs T+OFS increased disease-free survival (DFS) and distant recurrence free interval (DRFI), but not overall survival (OS), in premenopausal women with HR+ early BC (Francis…

Meredith M. Regan, ScD, Associate Professor of Medicine, Dana-Farber Cancer Institute/Harvard Medical School speaks about the SABCS 2021 Abstract – GS2-05 Randomized comparison of adjuvant aromatase inhibitor exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC): update of the combined TEXT and SOFT trials.Link to Abstract:https://www.sabcs.org/Portals/SABCS2016/2021%20SABCS/SABCS21_embargoedAbstracts_111921.pdf?ver=2021-11-19-141323-927Background:After 9 years of median follow-up (MFU), the updated combined SOFT+TEXT analysis demonstrated that adjuvant E+OFS vs T+OFS increased disease-free survival (DFS) and distant recurrence free interval (DRFI), but not overall survival (OS), in premenopausal women with HR+ early BC (Francis…

Nadia Harbeck, MD, PhD, is head of the Breast Center and holds the chair for Conservative Oncology at the Dept. of OB&GYN, University of Munich (LMU), Germany speaks about the SABCS Abstract – OT1-12-04 A phase 3, open-label trial of neoadjuvant trastuzumab deruxtecan (T-DXd) monotherapy or T-DXd followed by THP compared with ddAC-THP in patients with high-risk HER2-positive early-stage breast cancer (DESTINY-Breast11).Link to Abstract:https://www.sabcs.org/Portals/SABCS2016/2021%20SABCS/SABCS21_embargoedAbstracts_111921.pdf?ver=2021-11-19-141323-927Background:Trastuzumab + pertuzumab and polychemotherapy are the current standard of care (SOC) for neoadjuvant treatment of human epidermal growth factor receptor 2 (HER2)-positive early-stage breast cancer (EBC). Patients are exposed to short- and long-term toxicity as a…

Nadia Harbeck, MD, PhD, is head of the Breast Center and holds the chair for Conservative Oncology at the Dept. of OB&GYN, University of Munich (LMU), Germany speaks about the SABCS Abstract – OT1-12-04 A phase 3, open-label trial of neoadjuvant trastuzumab deruxtecan (T-DXd) monotherapy or T-DXd followed by THP compared with ddAC-THP in patients with high-risk HER2-positive early-stage breast cancer (DESTINY-Breast11).Link to Abstract:https://www.sabcs.org/Portals/SABCS2016/2021%20SABCS/SABCS21_embargoedAbstracts_111921.pdf?ver=2021-11-19-141323-927Background:Trastuzumab + pertuzumab and polychemotherapy are the current standard of care (SOC) for neoadjuvant treatment of human epidermal growth factor receptor 2 (HER2)-positive early-stage breast cancer (EBC). Patients are exposed to short- and long-term toxicity as a…

Gabriel Aleixo, MD from the Cleveland Clinic speaks about the SABCS Abstract – P1-08-04 The impact of sarcopenia and sarcopenic obesity detected by bioelectrical impedance analysis in patients with early breast cancer.Link to Abstract:https://www.sabcs.org/Portals/SABCS2016/2021%20SABCS/SABCS%202021%20Abstracts.pdf?ver=2021-11-19-080202-743&utm_source=Jaguar+Health%2C+Inc.+Investor+Contacts&utm_campaign=8777ae34f6-Earnings+Call+111417_COPY_01&utm_medium=email&utm_term=0_4612a17168-8777ae34f6-610272854&mc_cid=8777ae34f6&mc_eid=3a5efd49f4Background:Sarcopenia, or a loss of muscle mass, is linked to toxicity from chemotherapy and a shorter life expectancy in women with breast cancer (BC). Sarcopenic obesity, a condition in which patients lose muscle mass and gain adipose tissue, is linked to a slew of comorbidities and poor outcomes in British Columbia. To date, the majority of research have relied on computed tomography (CT) to gather the data…

Gabriel Aleixo, MD from the Cleveland Clinic speaks about the SABCS Abstract – P1-08-04 The impact of sarcopenia and sarcopenic obesity detected by bioelectrical impedance analysis in patients with early breast cancer.Link to Abstract:https://www.sabcs.org/Portals/SABCS2016/2021%20SABCS/SABCS%202021%20Abstracts.pdf?ver=2021-11-19-080202-743&utm_source=Jaguar+Health%2C+Inc.+Investor+Contacts&utm_campaign=8777ae34f6-Earnings+Call+111417_COPY_01&utm_medium=email&utm_term=0_4612a17168-8777ae34f6-610272854&mc_cid=8777ae34f6&mc_eid=3a5efd49f4Background:Sarcopenia, or a loss of muscle mass, is linked to toxicity from chemotherapy and a shorter life expectancy in women with breast cancer (BC). Sarcopenic obesity, a condition in which patients lose muscle mass and gain adipose tissue, is linked to a slew of comorbidities and poor outcomes in British Columbia. To date, the majority of research have relied on computed tomography (CT) to gather the data…

Monica Morrow, MD from Memorial Sloan Kettering Cancer Center speaks about the SABCS 2021 Presentation Is less (or more) axillary surgery needed in the genomic era?

Monica Morrow, MD from Memorial Sloan Kettering Cancer Center speaks about the SABCS 2021 Presentation Is less (or more) axillary surgery needed in the genomic era?

Aurélien Marabelle, M.D., Ph.D., Immuno-Oncologist from the Drug Development Department at Gustave Roussy Cancer Center speaks about SOT101 Shows Clinical Benefit in Patients with Advanced Solid Tumors.Link to https://sotio.com/news-publications/news/sot101-shows-clinical-benefit-in-patients-with-advanced-solid-tumorsNew data from the current Phase 1/1b AURELIO-03 study of SOT101, an IL-15 superagonist, as a monotherapy and in combination with pembrolizumab in patients with advanced/metastatic solid tumors were released today by SOTIO Biotech, a clinical-stage immuno-oncology business owned by PPF Group. The findings will be presented in three posters at the Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting, which will take place from November 10 to 14, 2021.The majority…

Aurélien Marabelle, M.D., Ph.D., Immuno-Oncologist from the Drug Development Department at Gustave Roussy Cancer Center speaks about SOT101 Shows Clinical Benefit in Patients with Advanced Solid Tumors.Link to https://sotio.com/news-publications/news/sot101-shows-clinical-benefit-in-patients-with-advanced-solid-tumorsNew data from the current Phase 1/1b AURELIO-03 study of SOT101, an IL-15 superagonist, as a monotherapy and in combination with pembrolizumab in patients with advanced/metastatic solid tumors were released today by SOTIO Biotech, a clinical-stage immuno-oncology business owned by PPF Group. The findings will be presented in three posters at the Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting, which will take place from November 10 to 14, 2021.The majority…

Oliver Dorigo, MD, Principal Investigator of the DeCidE1 study and Director of the Gynecologic Oncology Service at Stanford University speaks about the IMV Announces Final Topline Results of the DeCidE1 Clinical Trial in Advanced Recurrent Ovarian Cancer and the updated data from ESMO 2021.Link to Article:https://www.imv-inc.com/news-events/press-releases/detail/695/imv-announces-final-topline-results-of-the-decide1-clinicalIMV Inc., a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies for difficult-to-treat cancers, today announced the topline results of the DeCidE1 Phase 2 clinical trial evaluating maveropepimut-S (formerly known as DPX-Survivac) in subjects with advanced recurrent ovarian cancer.The details of these translational assessments have been submitted for presentation at upcoming scientific gatherings.The DeCidE1…

Oliver Dorigo, MD, Principal Investigator of the DeCidE1 study and Director of the Gynecologic Oncology Service at Stanford University speaks about the IMV Announces Final Topline Results of the DeCidE1 Clinical Trial in Advanced Recurrent Ovarian Cancer and the updated data from ESMO 2021.Link to Article:https://www.imv-inc.com/news-events/press-releases/detail/695/imv-announces-final-topline-results-of-the-decide1-clinicalIMV Inc., a clinical-stage biopharmaceutical company pioneering a novel class of immunotherapies for difficult-to-treat cancers, today announced the topline results of the DeCidE1 Phase 2 clinical trial evaluating maveropepimut-S (formerly known as DPX-Survivac) in subjects with advanced recurrent ovarian cancer.The details of these translational assessments have been submitted for presentation at upcoming scientific gatherings.The DeCidE1…

Drs. Ana Velázquez e Ivy Franco, participantes en el Programa de Embajadores de Educación para Pacientes GRACE de este año pasado, tienen una discusión para nuestra comunidad de habla hispana sobre Ensayos Clínicos. Para este video, los doctores Velázquez y Franco analizan por qué debería participar en un ensayo clínico y cómo. ¡Muchas gracias a nuestros patrocinadores #Lilly y #Genentech! Para obtener más información, visite http://cancerGRACE.org/. Para unirse a la conversación, visite https://cancergrace.org/forum. ********************************************************************** Drs. Ana Velazquez and Ivy Franco, participants in this past year’s GRACE Patient Education Ambassador Program, have a discussion for our Spanish-speaking community on Clinical Trials.…

¿Qué son los estudios clínicos? What are Clinical Trials? Drs. Ana Velázquez e Ivy Franco, participantes en el Programa de Embajadores de Educación para Pacientes GRACE de este año pasado, tienen una discusión para nuestra comunidad de habla hispana sobre Ensayos Clínicos. Para este video, los doctores Velázquez y Franco analizan exactamente qué es un ensayo clínico. ¡Muchas gracias a nuestros patrocinadores #Lilly y #Genentech! Para obtener más información, visite http://cancerGRACE.org/. Para unirse a la conversación, visite https://cancergrace.org/forum. ******************************************************************** Drs. Ana Velazquez and Ivy Franco, participants in this past year’s GRACE Patient Education Ambassador Program, have a discussion for our…

Dr. Rafeh Naqash, one of the participants in the GRACE Patient Education Ambassador Program, shares a fantastic video series on understanding clinical trials. For this series, Dr. Naqash speaks with Ivy Elkins, Patient Advocate and Lung Cancer Survivor and founder of the EGFR Resisters Patient Group, (https://egfrcancer.org/founders/) and Fumiko Chino, MD, a Radiation Oncologist with Memorial Sloan Kettering Cancer Center (https://www.mskcc.org/cancer-care/doc…). In this video, Drs. Naqash and Chino and Ms. Elkins discuss the cost of clinical trials, billing practices, emergency treatment, and other expenses. #clinicaltrial #genentech #lilly #cancerGRACE To join the conversation, visit https://cancergrace.org/forum. For more, please visit http://cancerGRACE.org/.

Dr. Rafeh Naqash, one of the participants in the GRACE Patient Education Ambassador Program, shares a fantastic video series on understanding clinical trials. For this series, Dr. Naqash speaks with Ivy Elkins, Patient Advocate and Lung Cancer Survivor and founder of the EGFR Resisters Patient Group, (https://egfrcancer.org/founders/) and Fumiko Chino, MD, a Radiation Oncologist with Memorial Sloan Kettering Cancer Center (https://www.mskcc.org/cancer-care/doc…). In this video, Drs. Naqash and Chino and Ms. Elkins discussclinical trials and provisions or resources for stress and mental health. #clinicaltrial #genentech #lilly #cancerGRACE To join the conversation, visit https://cancergrace.org/forum. For more, please visit http://cancerGRACE.org/.

Dr. Rafeh Naqash, one of the participants in the GRACE Patient Education Ambassador Program, shares a fantastic video series on understanding clinical trials. For this series, Dr. Naqash speaks with Ivy Elkins, Patient Advocate and Lung Cancer Survivor and founder of the EGFR Resisters Patient Group, (https://egfrcancer.org/founders/) and Fumiko Chino, MD, a Radiation Oncologist with Memorial Sloan Kettering Cancer Center (https://www.mskcc.org/cancer-care/doc…). In this video, Drs. Naqash and Chino and Ms. Elkins discuss what happens if you have to leave a clinical trial. #clinicaltrial #genentech #lilly #cancerGRACE To join the conversation, visit https://cancergrace.org/forum. For more, please visit http://cancerGRACE.org/.

Dr. Rafeh Naqash, one of the participants in the GRACE Patient Education Ambassador Program, shares a fantastic video series on understanding clinical trials. For this series, Dr. Naqash speaks with Ivy Elkins, Patient Advocate and Lung Cancer Survivor and founder of the EGFR Resisters Patient Group, (https://egfrcancer.org/founders/) and Fumiko Chino, MD, a Radiation Oncologist with Memorial Sloan Kettering Cancer Center (https://www.mskcc.org/cancer-care/doc…). In this video, Drs. Naqash and Chino and Ms. Elkins discuss if a trial could be the right fit even if your doctor doesn’t know about it. #clinicaltrial #genentech #lilly #cancerGRACE To join the conversation, visit https://cancergrace.org/forum. For more,…

Dr. Rafeh Naqash, one of the participants in the GRACE Patient Education Ambassador Program, shares a fantastic video series on understanding clinical trials. For this series, Dr. Naqash speaks with Ivy Elkins, Patient Advocate and Lung Cancer Survivor and founder of the EGFR Resisters Patient Group, (https://egfrcancer.org/founders/) and Fumiko Chino, MD, a Radiation Oncologist with Memorial Sloan Kettering Cancer Center (https://www.mskcc.org/cancer-care/doc…). In this video, Drs. Naqash and Chino and Ms. Elkins discuss potential side effects you might expect on a clinical trial and how you manage them. #clinicaltrial #genentech #lilly #cancerGRACE To join the conversation, visit https://cancergrace.org/forum. For more, please…

Dr. Rafeh Naqash, one of the participants in the GRACE Patient Education Ambassador Program, shares a fantastic video series on understanding clinical trials. For this series, Dr. Naqash speaks with Ivy Elkins, Patient Advocate and Lung Cancer Survivor and founder of the EGFR Resisters Patient Group, (https://egfrcancer.org/founders/) and Fumiko Chino, MD, a Radiation Oncologist with Memorial Sloan Kettering Cancer Center (https://www.mskcc.org/cancer-care/doc…). In this video, Drs. Naqash and Chino and Ms. Elkins discuss how being on a clinical trial can potentially impact your daily life. #clinicaltrial #genentech #lilly #cancerGRACE To join the conversation, visit https://cancergrace.org/forum. For more, please visit http://cancerGRACE.org/.

Dr. Rafeh Naqash, one of the participants in the GRACE Patient Education Ambassador Program, shares a fantastic video series on understanding clinical trials. For this series, Dr. Naqash speaks with Ivy Elkins, Patient Advocate and Lung Cancer Survivor and founder of the EGFR Resisters Patient Group, (https://egfrcancer.org/founders/) and Fumiko Chino, MD, a Radiation Oncologist with Memorial Sloan Kettering Cancer Center (https://www.mskcc.org/cancer-care/doc…). In this video, Drs. Naqash and Chino and Ms. Elkins discuss eligibility for clinical trials. #clinicaltrial #genentech #lilly #cancerGRACE To join the conversation, visit https://cancergrace.org/forum. For more, please visit http://cancerGRACE.org/.

Dr. Rafeh Naqash, one of the participants in the GRACE Patient Education Ambassador Program, shares a fantastic video series on understanding clinical trials. For this series, Dr. Naqash speaks with Ivy Elkins, Patient Advocate and Lung Cancer Survivor and founder of the EGFR Resisters Patient Group, (https://egfrcancer.org/founders/) and Fumiko Chino, MD, a Radiation Oncologist with Memorial Sloan Kettering Cancer Center (https://www.mskcc.org/cancer-care/doc…). In this video, Drs. Naqash and Chino and Ms. Elkins discuss what a ‘first-in-human’ trial means, and whether participants are a ‘guinea pig’. #clinicaltrial #genentech #lilly #cancerGRACE To join the conversation, visit https://cancergrace.org/forum. For more, please visit http://cancerGRACE.org/.

Dr. Rafeh Naqash, one of the participants in the GRACE Patient Education Ambassador Program, shares a fantastic video series on understanding clinical trials. For this series, Dr. Naqash speaks with Ivy Elkins, Patient Advocate and Lung Cancer Survivor and founder of the EGFR Resisters Patient Group, (https://egfrcancer.org/founders/) and Fumiko Chino, MD, a Radiation Oncologist with Memorial Sloan Kettering Cancer Center (https://www.mskcc.org/cancer-care/doc…). In this video, Drs. Naqash and Chino and Ms. Elkins discuss placebos and their use in phase 1 clinical trials, and how it differs from other phases. #clinicaltrial #genentech #lilly #cancerGRACE To join the conversation, visit https://cancergrace.org/forum. For more,…

Dr. Rafeh Naqash, one of the participants in the GRACE Patient Education Ambassador Program, shares a fantastic video series on understanding clinical trials. For this series, Dr. Naqash speaks with Ivy Elkins, Patient Advocate and Lung Cancer Survivor and founder of the EGFR Resisters Patient Group, (https://egfrcancer.org/founders/) and Fumiko Chino, MD, a Radiation Oncologist with Memorial Sloan Kettering Cancer Center (https://www.mskcc.org/cancer-care/doctors/fumiko-chino). In this video, Drs. Naqash and Chino and Ms. Elkins discuss the phases of clinical trials and what they mean. #clinicaltrial #genentech #lilly #cancerGRACE To join the conversation, visit https://cancergrace.org/forum. For more, please visit http://cancerGRACE.org/.

Dr. Rafeh Naqash, one of the participants in the GRACE Patient Education Ambassador Program, shares a fantastic video series on understanding clinical trials. For this series, Dr. Naqash speaks with Ivy Elkins, Patient Advocate and Lung Cancer Survivor and founder of the EGFR Resisters Patient Group, (https://egfrcancer.org/founders/) and Fumiko Chino, MD, a Radiation Oncologist with Memorial Sloan Kettering Cancer Center (https://www.mskcc.org/cancer-care/doc…). In this video, Drs. Naqash and Chino and Ms. Elkins discuss how medical data will be used and if it would be used without the participant’s knowledge. #clinicaltrial #genentech #lilly #cancerGRACE To join the conversation, visit https://cancergrace.org/forum. For more,…

Dr. Rafeh Naqash, one of the participants in the GRACE Patient Education Ambassador Program, shares a fantastic video series on understanding clinical trials. For this series, Dr. Naqash speaks with Ivy Elkins, Patient Advocate and Lung Cancer Survivor and founder of the EGFR Resisters Patient Group, (https://egfrcancer.org/founders/) and Fumiko Chino, MD, a Radiation Oncologist with Memorial Sloan Kettering Cancer Center (https://www.mskcc.org/cancer-care/doc…). In this video, Drs. Naqash and Chino and Ms. Elkins discuss whether clinical trials are only for people who have no other options. #clinicaltrial #genentech #lilly #cancerGRACE To join the conversation, visit https://cancergrace.org/forum. For more, please visit http://cancerGRACE.org/.

¿Que es la radioterapia, cuando es utilizada, y cuales son los efectos secundarios más comunes?La Dra. Ivy Franco, participante en el Programa de Embajadores de Educación para Pacientes GRACE de este año pasado, tiene una discusión para nuestra comunidad de habla hispana sobre la radioterapia.Para este video, el Dr. Franco analiza qué es la radioterapia, cuándo se usa y cuáles son algunos de los efectos secundarios comunes.¡Muchas gracias a nuestros patrocinadores #Lilly y #Genentech!Para obtener más información, visite http://cancerGRACE.org/. Para unirse a la conversación, visite https://cancergrace.org/forum.************************************************************************Dr. Ivy Franco, a participant in this past year’s GRACE Patient Education Ambassador Program, has…

Dr. Medhavi Gupta, one of the participants in this past year’s GRACE Patient Education Ambassador Program, shares a fantastic video series on Breast Cancer. For this series, Dr. Gupta discusses Metastatic Triple-Negative Breast Cancer with Dr. Aditya Bardai. Dr. Bardai is Assistant Professor of Medicine at Harvard Medical School and Attending Physician in Medical Oncology at Massachusetts General Hospital. In this video, Drs. Gupta and Bardai discuss Antibody-Drug Conjugate Treatment Options #breastcancer #Metastases #triplenegative #cancerGRACE #genentech #lilly To join the conversation, visit https://cancergrace.org/forum. For more, please visit http://cancerGRACE.org/.

Dr. Medhavi Gupta, one of the participants in this past year’s GRACE Patient Education Ambassador Program, shares a fantastic video series on Breast Cancer. For this first series, Dr. Gupta discusses Brain Metastases in Breast Cancer with Dr. Nancy Lin. Dr. Lin is Associate Chief, Division of Breast Oncology at the Susan F. Smith Center for Women’s Cancers, Associate Professor of Medicine and the Director for the Metastatic Breast Cancer Program and the Program for Patients with Breast Cancer Brain Metastases at Harvard In this video, Drs. Gupta and Lin discuss signs and symptoms that may indicate brain metastases in…

Dr. Medhavi Gupta, one of the participants in this past year’s GRACE Patient Education Ambassador Program, shares a fantastic video series on Breast Cancer. For this first series, Dr. Gupta discusses Surgical Management in Breast Cancer with Dr. Jessica Young. In this video, Drs. Gupta and Young discuss what to expect after surgery. #breastcancer #surgery #cancerGRACE #genentech #lilly For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

Dr. Medhavi Gupta, one of the participants in this past year’s GRACE Patient Education Ambassador Program, shares a fantastic video series on Breast Cancer. For this first series, Dr. Gupta discusses Brain Metastases in Breast Cancer with Dr. Nancy Lin. Dr. Lin is Associate Chief, Division of Breast Oncology at the Susan F. Smith Center for Women’s Cancers, and Associate Professor of Medicine and the Director for the Metastatic Breast Cancer Program and the Program for Patients with Breast Cancer Brain Metastases at Harvard. In this video, Drs. Gupta and Lin discuss the risks of developing brain metastases in breast…

Dr. Medhavi Gupta, one of the participants in this past year’s GRACE Patient Education Ambassador Program, shares a fantastic video series on Breast Cancer. For this first series, Dr. Gupta discusses Brain Metastases in Breast Cancer with Dr. Nancy Lin. Dr. Lin is Associate Chief, Division of Breast Oncology at the Susan F. Smith Center for Women’s Cancers, Associate Professor of Medicine and the Director for the Metastatic Breast Cancer Program and the Program for Patients with Breast Cancer Brain Metastases at Harvard In this video, Drs. Gupta and Lin discuss the prognosis and impact on survival in breast cancer…

Dr. Medhavi Gupta, one of the participants in this past year’s GRACE Patient Education Ambassador Program, shares a fantastic video series on Breast Cancer. For this first series, Dr. Gupta discusses Surgical Management in Breast Cancer with Dr. Jessica Young. In this video, Drs. Gupta and Young discuss body image and reconstructive surgery. #breastcancer #surgery #cancerGRACE #genentech #lilly For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

Dr. Medhavi Gupta, one of the participants in this past year’s GRACE Patient Education Ambassador Program, shares a fantastic video series on Breast Cancer. For this first series, Dr. Gupta discusses Surgical Management in Breast Cancer with Dr. Jessica Young. In this video, Drs. Gupta and Young discuss what to expect during surgery. #breastcancer #surgery #cancerGRACE #genentech #lilly For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

Dr. Medhavi Gupta, one of the participants in this past year’s GRACE Patient Education Ambassador Program, shares a fantastic video series on Breast Cancer. For this first series, Dr. Gupta discusses Surgical Management in Breast Cancer with Dr. Jessica Young. In this video, Drs. Gupta and Young discuss surgical management in breast cancer, and the surgical removal of lymph nodes – sentinel lymph node biopsy vs. axillary lymph node dissection (ALND). #breastcancer #surgery #cancerGRACE #genentech #lilly For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

Dr. Medhavi Gupta, one of the participants in this past year’s GRACE Patient Education Ambassador Program, shares a fantastic video series on Breast Cancer. For this first series, Dr. Gupta discusses Surgical Management in Breast Cancer with Dr. Jessica Young. In this video, Drs. Gupta and Young discuss surgical management in breast cancer and prophylactic mastectomy on the opposite breast. #breastcancer #surgery #cancerGRACE #genentech #lilly For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

Dr. Medhavi Gupta, one of the participants in this past year’s GRACE Patient Education Ambassador Program, has presented GRACE with a fantastic video series on Breast Cancer. For this first series, Dr. Gupta discusses Surgical Management in Breast Cancer with Dr. Jessica Young. In this video, Drs. Gupta and Young discuss long term outcomes in breast-conserving therapy vs. mastectomy. Many thanks to our sponsors #Lilly and #Genentech! For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

Dr. Medhavi Gupta, one of the participants in this past year’s GRACE Patient Education Ambassador Program, shares a fantastic video series on Breast Cancer. For this first series, Dr. Gupta discusses Surgical Management in Breast Cancer with Dr. Jessica Young. In this video, Drs. Gupta and Young discuss the role of different types of surgery and the management of patients with breast cancer. #breastcancer #surgery #cancerGRACE #genentech #lilly For more, please visit http://cancerGRACE.org/. To join the conversation, visit https://cancergrace.org/forum.

Videos from the 2020 Targeted Therapies Patient Forum are still available! This past event’s live-online presentations and discussions were launched by our Event Chair, Luis E. Raez, MD FACP FCCP, Member of the GRACE Board of Directors, President of the Florida Society of Clinical Oncology (FLASCO), and Chief Scientific Officer & Medical Director at Memorial Cancer Institute. The day-long event featured top oncologists in their field, presenting the most current and emerging information in targeted therapies for patients and caregivers living with lung cancer. In this video from the ALK/ROS session from the event, the panel discusses TKIs for a…

Videos from the 2020 Targeted Therapies Patient Forum are still available! This past event’s live-online presentations and discussions were launched by our Event Chair, Luis E. Raez, MD FACP FCCP, Member of the GRACE Board of Directors, President of the Florida Society of Clinical Oncology (FLASCO), and Chief Scientific Officer & Medical Director at Memorial Cancer Institute. The day-long event featured top oncologists in their field, presenting the most current and emerging information in targeted therapies for patients and caregivers living with lung cancer. In this video from the ALK/ROS session from the event, the panel discusses ROS1+ patients who…

Videos from the 2020 Targeted Therapies Patient Forum are still available! This past event’s live-online presentations and discussions were launched by our Event Chair, Luis E. Raez, MD FACP FCCP, Member of the GRACE Board of Directors, President of the Florida Society of Clinical Oncology (FLASCO), and Chief Scientific Officer & Medical Director at Memorial Cancer Institute. The day-long event featured top oncologists in their field, presenting the most current and emerging information in targeted therapies for patients and caregivers living with lung cancer. In this video from the ALK/ROS session from the event, the panel discusses the differences in…

Videos from the 2020 Targeted Therapies Patient Forum are still available! This past event’s live-online presentations and discussions were launched by our Event Chair, Luis E. Raez, MD FACP FCCP, Member of the GRACE Board of Directors, President of the Florida Society of Clinical Oncology (FLASCO), and Chief Scientific Officer & Medical Director at Memorial Cancer Institute. The day-long event featured top oncologists in their field, presenting the most current and emerging information in targeted therapies for patients and caregivers living with lung cancer. In this video from the ALK/ROS session from the event, the panel discusses how treatment would…

Videos from the 2020 Targeted Therapies Patient Forum are still available! This past event’s live-online presentations and discussions were launched by our Event Chair, Luis E. Raez, MD FACP FCCP, Member of the GRACE Board of Directors, President of the Florida Society of Clinical Oncology (FLASCO), and Chief Scientific Officer & Medical Director at Memorial Cancer Institute. The day-long event featured top oncologists in their field, presenting the most current and emerging information in targeted therapies for patients and caregivers living with lung cancer. In this video from the ALK/ROS session from the event, the panel discusses what we know…

Videos from the 2020 Targeted Therapies Patient Forum are still available! This past event’s live-online presentations and discussions were launched by our Event Chair, Luis E. Raez, MD FACP FCCP, Member of the GRACE Board of Directors, President of the Florida Society of Clinical Oncology (FLASCO), and Chief Scientific Officer & Medical Director at Memorial Cancer Institute. The day-long event featured top oncologists in their field, presenting the most current and emerging information in targeted therapies for patients and caregivers living with lung cancer. In this video from the ALK/ROS session from the event, the panel discusses whether ROS1+ patients…

Videos from the 2020 Targeted Therapies Patient Forum are still available! This past event’s live-online presentations and discussions were launched by our Event Chair, Luis E. Raez, MD FACP FCCP, Member of the GRACE Board of Directors, President of the Florida Society of Clinical Oncology (FLASCO), and Chief Scientific Officer & Medical Director at Memorial Cancer Institute. The day-long event featured top oncologists in their field, presenting the most current and emerging information in targeted therapies for patients and caregivers living with lung cancer. In this video from the ALK/ROS session from the event, the panel discusses using circulating tumor…

Videos from the 2020 Targeted Therapies Patient Forum are still available! This past event’s live-online presentations and discussions were launched by our Event Chair, Luis E. Raez, MD FACP FCCP, Member of the GRACE Board of Directors, President of the Florida Society of Clinical Oncology (FLASCO), and Chief Scientific Officer & Medical Director at Memorial Cancer Institute. The day-long event featured top oncologists in their field, presenting the most current and emerging information in targeted therapies for patients and caregivers living with lung cancer. In this video from the ALK session from the event, the panel discusses the next treatment…

Videos from the 2020 Targeted Therapies Patient Forum are still available! This past event’s live-online presentations and discussions were launched by our Event Chair, Luis E. Raez, MD FACP FCCP, Member of the GRACE Board of Directors, President of the Florida Society of Clinical Oncology (FLASCO), and Chief Scientific Officer & Medical Director at Memorial Cancer Institute. The day-long event featured top oncologists in their field, presenting the most current and emerging information in targeted therapies for patients and caregivers living with lung cancer. In this video from the ALK session from the event, the panel discusses what is next…

Videos from the 2020 Targeted Therapies Patient Forum are still available! This past event’s live-online presentations and discussions were launched by our Event Chair, Luis E. Raez, MD FACP FCCP, Member of the GRACE Board of Directors, President of the Florida Society of Clinical Oncology (FLASCO), and Chief Scientific Officer & Medical Director at Memorial Cancer Institute. The day-long event featured top oncologists in their field, presenting the most current and emerging information in targeted therapies for patients and caregivers living with lung cancer. In this video from the ROS session from the event, the panel discusses what information we…

Join us for the 2021 Targeted Therapies Patient Forum, presented Live-Online on July 17, 2021, at 10:00 am eastern time! More information is available at cancerGRACE.org. But meanwhile — Videos from the 2020 Targeted Therapies Patient Forum are still available! This past event’s live-online presentations and discussions were launched by our Event Chair, Luis E. Raez, MD FACP FCCP, Member of the GRACE Board of Directors, President of the Florida Society of Clinical Oncology (FLASCO), and Chief Scientific Officer & Medical Director at Memorial Cancer Institute. The day-long event featured top oncologists in their field, presenting the most current and…

Join us for the 2021 Targeted Therapies Patient Forum, presented Live-Online on July 17, 2021, at 10:00 am eastern time! More information is available at cancerGRACE.org. But meanwhile — Videos from the 2020 Targeted Therapies Patient Forum are still available! This past event’s live-online presentations and discussions were launched by our Event Chair, Luis E. Raez, MD FACP FCCP, Member of the GRACE Board of Directors, President of the Florida Society of Clinical Oncology (FLASCO), and Chief Scientific Officer & Medical Director at Memorial Cancer Institute. The day-long event featured top oncologists in their field, presenting the most current and…

Videos from the 2020 Targeted Therapies Patient Forum are still available! This past event’s live-online presentations and discussions were launched by our Event Chair, Luis E. Raez, MD FACP FCCP, Member of the GRACE Board of Directors, President of the Florida Society of Clinical Oncology (FLASCO), and Chief Scientific Officer & Medical Director at Memorial Cancer Institute. The day-long event featured top oncologists in their field, presenting the most current and emerging information in targeted therapies for patients and caregivers living with lung cancer. In this video from the ALK session from the event, the panel discusses the reducing dosage…

Join us for the 2021 Targeted Therapies Patient Forum, presented Live-Online on July 17, 2021, at 10:00 am eastern time! But meanwhile — Videos from the 2020 Targeted Therapies Patient Forum are still available! This past event’s live-online presentations and discussions were launched by our Event Chair, Luis E. Raez, MD FACP FCCP, Member of the GRACE Board of Directors, President of the Florida Society of Clinical Oncology (FLASCO), and Chief Scientific Officer & Medical Director at Memorial Cancer Institute. The day-long event featured top oncologists in their field, presenting the most current and emerging information in targeted therapies for…

Join us for the 2021 Targeted Therapies Patient Forum, presented Live-Online on July 17, 2021, at 10:00 am eastern time! But meanwhile — Videos from the 2020 Targeted Therapies Patient Forum are still available! This past event’s live-online presentations and discussions were launched by our Event Chair, Luis E. Raez, MD FACP FCCP, Member of the GRACE Board of Directors, President of the Florida Society of Clinical Oncology (FLASCO), and Chief Scientific Officer & Medical Director at Memorial Cancer Institute. The day-long event featured top oncologists in their field, presenting the most current and emerging information in targeted therapies for…

Join us for the 2021 Targeted Therapies Patient Forum, presented Live-Online on July 17, 2021, at 10:00 am eastern time! More information is available at cancerGRACE.org. But meanwhile — Videos from the 2020 Targeted Therapies Patient Forum are still available! This past event’s live-online presentations and discussions were launched by our Event Chair, Luis E. Raez, MD FACP FCCP, Member of the GRACE Board of Directors, President of the Florida Society of Clinical Oncology (FLASCO), and Chief Scientific Officer & Medical Director at Memorial Cancer Institute. The day-long event featured top oncologists in their field, presenting the most current and…

Join us for the 2021 Targeted Therapies Patient Forum, presented Live-Online on July 17, 2021, at 10:00 am eastern time! More information is available at cancerGRACE.org. But meanwhile — Videos from the 2020 Targeted Therapies Patient Forum are still available! This past event’s live-online presentations and discussions were launched by our Event Chair, Luis E. Raez, MD FACP FCCP, Member of the GRACE Board of Directors, President of the Florida Society of Clinical Oncology (FLASCO), and Chief Scientific Officer & Medical Director at Memorial Cancer Institute. The day-long event featured top oncologists in their field, presenting the most current and…

Join us for the 2021 Targeted Therapies Patient Forum, presented Live-Online on July 17, 2021, at 10:00 am eastern time! More information is available at cancerGRACE.org. But meanwhile — Videos from the 2020 Targeted Therapies Patient Forum are still available! This past event’s live-online presentations and discussions were launched by our Event Chair, Luis E. Raez, MD FACP FCCP, Member of the GRACE Board of Directors, President of the Florida Society of Clinical Oncology (FLASCO), and Chief Scientific Officer & Medical Director at Memorial Cancer Institute. The day-long event featured top oncologists in their field, presenting the most current and…

Join us for the 2021 Targeted Therapies Patient Forum, presented Live-Online on July 17, 2021, at 10:00 am eastern time! More information is available at cancerGRACE.org. But meanwhile — Videos from the 2020 Targeted Therapies Patient Forum are still available! This past event’s live-online presentations and discussions were launched by our Event Chair, Luis E. Raez, MD FACP FCCP, Member of the GRACE Board of Directors, President of the Florida Society of Clinical Oncology (FLASCO), and Chief Scientific Officer & Medical Director at Memorial Cancer Institute. The day-long event featured top oncologists in their field, presenting the most current and…

En esta serie de videos, los Dres. Luis Raez, Estalemari Rodriguez y Ticiana Leal tener discusiones sinceras sobre el cáncer y COVID-19. En este tiempo continuo de distanciamiento social y limitación de la exposición clínica, los médicos se sentaron para discutir algunas de las preguntas que todos escuchamos sobre estos tiempos sin precedentes y cómo afectan principalmente a los pacientes con cáncer. En este video, la discusión gira en torno al impacto de la pandemia COVID-19 en la atención de los pacientes con cáncer. Gracias a Exelixis y Merck por su apoyo a este programa. Para obtener más información, visite…

En esta serie de videos, los Dres. Luis Raez, Estalemari Rodriguez y Ticiana Leal tener discusiones sinceras sobre el cáncer y COVID-19. En este tiempo continuo de distanciamiento social y limitación de la exposición clínica, los médicos se sentaron a discutir algunas de las preguntas que todos escuchamos con respecto a estos tiempos sin precedentes y cómo afectan principalmente a los pacientes con cáncer. En este video, la discusión gira en torno al uso de la telemedicina en el tratamiento de pacientes con cáncer. Gracias a #Exelixis y #Merck por su apoyo a este programa. Para obtener más información, visite…

En esta serie de videos, los Dres. Luis Raez, Estalemari Rodríguez y Ticiana Leal tienen conversaciones sinceras sobre el cáncer y el COVID-19. En este tiempo continuo de distanciamiento social y limitación de la exposición clínica, los médicos se sentaron a discutir algunas de las preguntas que todos escuchamos con respecto a estos tiempos sin precedentes y cómo afectan principalmente a los pacientes con cáncer. En este video, la discusión gira en torno al uso de la vacuna COVID-19 en pacientes con cáncer. Gracias a #Exelixis y #Merck por su apoyo a este programa. Para obtener más información, visite https://cancergrace.org.…

Richard A. Van Etten MD, Ph.D., Director of the NCI-designated Chao Family Comprehensive Cancer Center and member of the Division of Hematology/Oncology at the University of California, Irvine, Senior Associate Dean & Associate Vice Chancellor for Cancer University of California, Irvine speaks about Helio Health and Fulgent Genetics Announce Late-Breaking Positive Performance Data of HelioLiverâ„¢ for Early Liver Cancer Detection.Link to Article:https://www.prnewswire.com/news-releases/helio-health-and-fulgent-genetics-announce-late-breaking-positive-performance-data-of-helioliver-for-early-liver-cancer-detection-301418252.htmlHelio Health and its commercial partner, Fulgent Genetics, Inc., presented fresh data at AASLD today proving the effectiveness of HelioLiver in detecting hepatocellular carcinoma in its early stages (HCC). HelioLiver’s sensitivity was 76 percent in early-stage HCC and 85…

Richard A. Van Etten MD, Ph.D., Director of the NCI-designated Chao Family Comprehensive Cancer Center and member of the Division of Hematology/Oncology at the University of California, Irvine, Senior Associate Dean & Associate Vice Chancellor for Cancer University of California, Irvine speaks about Helio Health and Fulgent Genetics Announce Late-Breaking Positive Performance Data of HelioLiverâ„¢ for Early Liver Cancer Detection.Link to Article:https://www.prnewswire.com/news-releases/helio-health-and-fulgent-genetics-announce-late-breaking-positive-performance-data-of-helioliver-for-early-liver-cancer-detection-301418252.htmlHelio Health and its commercial partner, Fulgent Genetics, Inc., presented fresh data at AASLD today proving the effectiveness of HelioLiver in detecting hepatocellular carcinoma in its early stages (HCC). HelioLiver’s sensitivity was 76 percent in early-stage HCC and 85…

Philip O. Scumpia, MD, Ph.D. and Professor Aydogan Ozcan, Ph.D. from UCLA Health and UCLA Samueli Electrical & Computer Engineering speak about New Imaging Technology Developed by UCLA Research Team May Reduce Need for Skin Biopsies.Link to Article:https://samueli.ucla.edu/new-imaging-technology-developed-by-ucla-research-team-may-reduce-need-for-skin-biopsies/Your dermatologist takes photographs of a suspicious-looking lesion and rapidly produces a detailed, microscopic image of the skin instead of surgically extracting a sample of skin, sending it to a lab, and waiting several days for findings.According to a new article published today in Light: Science & Applications, a journal of the Springer Nature Group, this could become commonplace in clinics as a…

Philip O. Scumpia, MD, Ph.D. and Professor Aydogan Ozcan, Ph.D. from UCLA Health and UCLA Samueli Electrical & Computer Engineering speak about New Imaging Technology Developed by UCLA Research Team May Reduce Need for Skin Biopsies.Link to Article:https://samueli.ucla.edu/new-imaging-technology-developed-by-ucla-research-team-may-reduce-need-for-skin-biopsies/Your dermatologist takes photographs of a suspicious-looking lesion and rapidly produces a detailed, microscopic image of the skin instead of surgically extracting a sample of skin, sending it to a lab, and waiting several days for findings.According to a new article published today in Light: Science & Applications, a journal of the Springer Nature Group, this could become commonplace in clinics as a…

Kevan Shokat, Ph.D., Professor, Department of Cellular and Molecular Pharmacology, at the University of California, San Francisco, and Investigator of the Howard Hughes Medical Institute for discovering a method to inhibit the mutant KRAS protein – a common driver of the growth of lung cancer as well as colorectal and pancreatic cancer. Speaks about Kevan Shokat Ph.D. To Be Awarded The First SWCRF Breakthrough Science Award.Link to Article:https://www.waxmancancer.org/about-us/newsroom/press-releases/kevan-shokat-ph-d-to-be-awarded-the-first-swcrf-breakthrough-science-award/Dr. Kevan Shokat, Professor of Cellular and Molecular Pharmacology at the University of California, San Francisco, and Investigator of the Howard Hughes Medical Institute, will receive the Samuel Waxman Cancer Research Foundation’s first…

John Mascarenhas, MD from the Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai speaks about the U.S. FDA Approves BESREMi® (ropeginterferon alfa-2b-njft) as the Only Interferon for Adults With Polycythemia Vera.Link to Abstract:https://www.businesswire.com/news/home/20211112005909/en/U.S.-FDA-Approves-BESREMi%C2%AE-ropeginterferon-alfa-2b-njft-as-the-Only-Interferon-for-Adults-With-Polycythemia-VeraThe US Food and Drug Administration (FDA) has approved BESREMi® (ropeginterferon alfa-2b-njft) for the treatment of adults with polycythemia vera. PharmaEssentia Corporation, a global biopharmaceutical innovator based in Taiwan, is leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology (PV).BESREMi is a novel monopegylated, long-acting interferon that has been shown to have cellular effects on polycythemia vera bone marrow. BESREMi…

John Mascarenhas, MD from the Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai speaks about the U.S. FDA Approves BESREMi® (ropeginterferon alfa-2b-njft) as the Only Interferon for Adults With Polycythemia Vera.Link to Abstract:https://www.businesswire.com/news/home/20211112005909/en/U.S.-FDA-Approves-BESREMi%C2%AE-ropeginterferon-alfa-2b-njft-as-the-Only-Interferon-for-Adults-With-Polycythemia-VeraThe US Food and Drug Administration (FDA) has approved BESREMi® (ropeginterferon alfa-2b-njft) for the treatment of adults with polycythemia vera. PharmaEssentia Corporation, a global biopharmaceutical innovator based in Taiwan, is leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology (PV).BESREMi is a novel monopegylated, long-acting interferon that has been shown to have cellular effects on polycythemia vera bone marrow. BESREMi…

Kevan Shokat, Ph.D., Professor, Department of Cellular and Molecular Pharmacology, at the University of California, San Francisco, and Investigator of the Howard Hughes Medical Institute for discovering a method to inhibit the mutant KRAS protein – a common driver of the growth of lung cancer as well as colorectal and pancreatic cancer. Speaks about Kevan Shokat Ph.D. To Be Awarded The First SWCRF Breakthrough Science Award.Link to Article:https://www.waxmancancer.org/about-us/newsroom/press-releases/kevan-shokat-ph-d-to-be-awarded-the-first-swcrf-breakthrough-science-award/Dr. Kevan Shokat, Professor of Cellular and Molecular Pharmacology at the University of California, San Francisco, and Investigator of the Howard Hughes Medical Institute, will receive the Samuel Waxman Cancer Research Foundation’s first…

Dea Slade, BSc, MSc, Ph.D., Junior group leader, Max F. Perutz Laboratories, University of Vienna speaks about PHF3 regulates neuronal gene expression through the Pol II CTD reader domain SPOC.Link to Abstract:https://www.nature.com/articles/s41467-021-26360-2Abstract:The C-terminal domain (CTD) of RNA polymerase II (Pol IIbiggest )’s subunit is a transcription and RNA processing control center. PHD-finger protein 3 (PHF3) is a transcription and mRNA stability regulator that binds onto the Pol II CTD via its SPOC domain. SPOC is a CTD reader domain that binds two phosphorylated Serine-2 tags in neighboring CTD repeats preferentially. PHF3 promotes the separation of phosphorylated Pol II into liquid…

Dea Slade, BSc, MSc, Ph.D., Junior group leader, Max F. Perutz Laboratories, University of Vienna speaks about PHF3 regulates neuronal gene expression through the Pol II CTD reader domain SPOC.Link to Abstract:https://www.nature.com/articles/s41467-021-26360-2Abstract:The C-terminal domain (CTD) of RNA polymerase II (Pol IIbiggest )’s subunit is a transcription and RNA processing control center. PHD-finger protein 3 (PHF3) is a transcription and mRNA stability regulator that binds onto the Pol II CTD via its SPOC domain. SPOC is a CTD reader domain that binds two phosphorylated Serine-2 tags in neighboring CTD repeats preferentially. PHF3 promotes the separation of phosphorylated Pol II into liquid…

Dr. Erika Hamilton of Sarah Cannon Research Institute chats with Drs. West & Aggarwal about how clinical trials & medical practice have changed after COVID-19, how the field of breast cancer has evolved, & how social media has created a global community.

Oscar Mesa, MD, MSC, Global Director, Health Economics, outcomes research and Market Access Critical care at Mallinckrodt. Speaks about Mallinckrodt and Terumo Blood and Cell Technologies Announce Positive Recommendations in Australia for Public Funding of UVADEX® (methoxsalen) for ECP Administration with the THERAKOS® CELLEX® Photopheresis System for Chronic Graft Versus Host Disease (cGvHD) in Adults.Link to Article:https://www.mallinckrodt.com/about/news-and-media/news-detail/?id=28736https://therakos.eu/Mallinckrodt plc (OTCMKTS: MNKKQ), a global biopharmaceutical company, and Terumo Blood and Cell Technologies, a global leader in blood component, therapeutic apheresis, and cellular technologies, as well as the exclusive distributor of the Therakos extracorporeal photopheresis (ECP) platform in Australia, announced today that the…

Oscar Mesa, MD, MSC, Global Director, Health Economics, outcomes research and Market Access Critical care at Mallinckrodt. Speaks about Mallinckrodt and Terumo Blood and Cell Technologies Announce Positive Recommendations in Australia for Public Funding of UVADEX® (methoxsalen) for ECP Administration with the THERAKOS® CELLEX® Photopheresis System for Chronic Graft Versus Host Disease (cGvHD) in Adults.Link to Article:https://www.mallinckrodt.com/about/news-and-media/news-detail/?id=28736https://therakos.eu/Mallinckrodt plc (OTCMKTS: MNKKQ), a global biopharmaceutical company, and Terumo Blood and Cell Technologies, a global leader in blood component, therapeutic apheresis, and cellular technologies, as well as the exclusive distributor of the Therakos extracorporeal photopheresis (ECP) platform in Australia, announced today that the…

Ethan Basch, MD, MSc from Lineberger Comprehensive Cancer Center, University of North Carolina speaks about Clinical Utility and User Perceptions of a Digital System for Electronic Patient-Reported Symptom Monitoring During Routine Cancer Care: Findings From the PRO-TECT Trial.   Link to Abstract: https://ascopubs.org/doi/10.1200/CCI.20.00081     ABSTRACT   PURPOSE   During ordinary oncology practice, there is growing interest in using digital tools for remote monitoring of patients’ symptoms. The therapeutic value and user impressions of these devices are both unknown.   METHODS   PRO-TECT is a multicenter experiment assessing the use of electronic patient-reported outcomes (ePROs) in persons with advanced and…

Ethan Basch, MD, MSc from Lineberger Comprehensive Cancer Center, University of North Carolina speaks about Clinical Utility and User Perceptions of a Digital System for Electronic Patient-Reported Symptom Monitoring During Routine Cancer Care: Findings From the PRO-TECT Trial.   Link to Abstract: https://ascopubs.org/doi/10.1200/CCI.20.00081     ABSTRACT   PURPOSE   During ordinary oncology practice, there is growing interest in using digital tools for remote monitoring of patients’ symptoms. The therapeutic value and user impressions of these devices are both unknown.   METHODS   PRO-TECT is a multicenter experiment assessing the use of electronic patient-reported outcomes (ePROs) in persons with advanced and…

Nima Sharifi, MD, Director, Center for GU Malignancies Research at the Cleveland Clinic speaks about Gut Microbiome-Dependent Metabolic Pathways and Risk of Lethal Prostate Cancer: Prospective Analysis of a PLCO Cancer Screening Trial Cohort. Link to Article:https://newsroom.clevelandclinic.org/2021/10/28/cleveland-clinic-study-links-gut-microbiome-and-aggressive-prostate-cancer/For the first time, Cleveland Clinic researchers have discovered that diet-related chemicals in the stomach are linked to aggressive prostate cancer, implying that dietary changes could help reduce risk. The study’s findings were published in the journal Cancer Epidemiology, Biomarkers & Prevention.While further research is needed, lead author Nima Sharifi, M.D., believes the findings from the team’s review of over 700 individuals could have…

Nima Sharifi, MD, Director, Center for GU Malignancies Research at the Cleveland Clinic speaks about Gut Microbiome-Dependent Metabolic Pathways and Risk of Lethal Prostate Cancer: Prospective Analysis of a PLCO Cancer Screening Trial Cohort.Link to Article:https://newsroom.clevelandclinic.org/2021/10/28/cleveland-clinic-study-links-gut-microbiome-and-aggressive-prostate-cancer/For the first time, Cleveland Clinic researchers have discovered that diet-related chemicals in the stomach are linked to aggressive prostate cancer, implying that dietary changes could help reduce risk. The study’s findings were published in the journal Cancer Epidemiology, Biomarkers & Prevention.While further research is needed, lead author Nima Sharifi, M.D., believes the findings from the team’s review of over 700 individuals could have therapeutic…

Dr. Leora Horn, having recently moved from academic medicine to AstraZeneca, talks with hosts Charu Aggarwal & Jack West about the decision to change roles, her efforts to balance work & family, & how to cultivate opportunities for junior faculty.

Todd William Ridky, M.D., Ph.D., Physician Scientist, Associate Professor of Dermatology at the Pearlman School of Medicine, University of Pennsylvania speaks about Drugs Designed for Prostate Cancer Show Promise for Treating Melanoma in Men.Link to Article:https://www.pennmedicine.org/news/news-releases/2021/october/drugs-designed-for-prostate-cancer-show-promise-for-treating-melanoma-in-menAccording to current research, testosterone enhances melanoma proliferation in melanoma cells by activating ZIP9 (encoded by the SLC39A9 gene), a zinc transporter that is not intentionally targeted by any known treatments but is abundantly expressed in human melanoma. Researchers at the University of Pennsylvania’s Perelman School of Medicine used melanoma models in mice to demonstrate that medications that target androgen receptors (AR) in prostate cancer…

Todd William Ridky, M.D., Ph.D., Physician Scientist, Associate Professor of Dermatology at the Pearlman School of Medicine, University of Pennsylvania speaks about Drugs Designed for Prostate Cancer Show Promise for Treating Melanoma in Men.Link to Article:https://www.pennmedicine.org/news/news-releases/2021/october/drugs-designed-for-prostate-cancer-show-promise-for-treating-melanoma-in-menAccording to current research, testosterone enhances melanoma proliferation in melanoma cells by activating ZIP9 (encoded by the SLC39A9 gene), a zinc transporter that is not intentionally targeted by any known treatments but is abundantly expressed in human melanoma. Researchers at the University of Pennsylvania’s Perelman School of Medicine used melanoma models in mice to demonstrate that medications that target androgen receptors (AR) in prostate cancer…

Dr. Rupal O’Quinn is a cardiologist in Philadelphia who is affiliated with both Penn Presbyterian Medical Center and Pennsylvania Hospital. She graduated from Rutgers Robert Wood Johnson Medical School with her medical degree. In this video Dr. O’Quinn speaks about her research in Cardiac Magnetic Resonance in Cardio-Oncology: Advantages, Importance of Expediency, and Considerations to Navigate Pre-Authorization.Link to Abstract-https://www.jacc.org/doi/10.1016/j.jaccao.2021.04.011Abstract-As the scope of cardio-oncology expands dramatically, both in terms of the number of people impacted and the sorts of therapy it involves, diagnosing acute and late cardiotoxicity from cancer therapeutics has become increasingly crucial. Cardiac magnetic resonance (CMR) is a tool…

Dr. Rupal O’Quinn is a cardiologist in Philadelphia who is affiliated with both Penn Presbyterian Medical Center and Pennsylvania Hospital. She graduated from Rutgers Robert Wood Johnson Medical School with her medical degree. In this video Dr. O’Quinn speaks about her research in Cardiac Magnetic Resonance in Cardio-Oncology: Advantages, Importance of Expediency, and Considerations to Navigate Pre-Authorization.Link to Abstract-https://www.jacc.org/doi/10.1016/j.jaccao.2021.04.011Abstract-As the scope of cardio-oncology expands dramatically, both in terms of the number of people impacted and the sorts of therapy it involves, diagnosing acute and late cardiotoxicity from cancer therapeutics has become increasingly crucial. Cardiac magnetic resonance (CMR) is a tool…

Dr. Javier Valero-Elizondo works as a Research Associate at the Center for Outcomes Research at the Houston Methodist Research Institute. In this video, Dr. Valero-Elizondo speaks about Atherosclerotic Cardiovascular Disease, Cancer, and Financial Toxicity Among Adults in the United States.Link to Abstract-https://www.jacc.org/doi/10.1016/j.jaccao.2021.02.006AbstractBackgroundFinancial toxicity (FT) is a well-known adverse effect of the high costs of cancer treatment. According to recent studies, a considerable proportion of people with atherosclerotic cardiovascular disease (ASCVD) suffer from FT and its effects.ObjectivesThe goal of this study was to compare FT in those who had neither ASCVD nor cancer, as well as those who had ASCVD but…

Dr. Javier Valero-Elizondo works as a Research Associate at the Center for Outcomes Research at the Houston Methodist Research Institute. In this video, Dr. Valero-Elizondo speaks about Atherosclerotic Cardiovascular Disease, Cancer, and Financial Toxicity Among Adults in the United States.Link to Abstract-https://www.jacc.org/doi/10.1016/j.jaccao.2021.02.006AbstractBackgroundFinancial toxicity (FT) is a well-known adverse effect of the high costs of cancer treatment. According to recent studies, a considerable proportion of people with atherosclerotic cardiovascular disease (ASCVD) suffer from FT and its effects.ObjectivesThe goal of this study was to compare FT in those who had neither ASCVD nor cancer, as well as those who had ASCVD but…

Carla R. Lamb, MD an interventional pulmonologist at Lahey Hospital & Medical Center speaks about Veracyte Announces New Expanded Data At Chest Underscoring Percepta Nasal Swab Test’s Ability To Improve Early Lung Cancer Assessment. Link to Article:https://investor.veracyte.com/news-releases/news-release-details/veracyte-announces-new-expanded-data-chest-underscoring-perceptaVeracyte, Inc. reported today that new expanded clinical validation data back up the company’s noninvasive Percepta Nasal Swab test’s ability to help clinicians better identify lung cancer risk in patients with lung nodules. The data also suggest that the test performs well in the clinic across a wide range of nodule sizes and cancer stages in current and former smokers, as well as individuals…

Carla R. Lamb, MD an interventional pulmonologist at Lahey Hospital and Medical Center speaks about Veracyte Announces New Expanded Data At Chest Underscoring Percepta Nasal Swab Test’s Ability To Improve Early Lung Cancer Assessment. Link to Article:https://investor.veracyte.com/news-releases/news-release-details/veracyte-announces-new-expanded-data-chest-underscoring-perceptaVeracyte, Inc. reported today that new expanded clinical validation data back up the company’s noninvasive Percepta Nasal Swab test’s ability to help clinicians better identify lung cancer risk in patients with lung nodules. The data also suggest that the test performs well in the clinic across a wide range of nodule sizes and cancer stages in current and former smokers, as well as individuals…

Meredith McKean, MD, Associate Director, Melanoma and Skin Cancer Research Program at Sarah Cannon Research Institute speaks about ESMO 2021 Abstract – 525P – Efficacy, safety, pharmacokinetic (PK) and pharmacodynamic (PD) data from phase I dose escalation of a novel therapeutic peptide, ST101, targeting the oncogenic transcription factor C/EBPβ, in patients (pts) with advanced and metastatic solid tumors.Link to Abstract:https://oncologypro.esmo.org/meeting-resources/esmo-congress-2021/efficacy-safety-pharmacokinetic-pk-and-pharmacodynamic-pd-data-from-phase-i-dose-escalation-of-a-novel-therapeutic-peptide-st101-targeting 525P Abstract:History:CCAAT/enhancer-binding protein (C/EBP), an oncogenic transcription factor, promotes tumor survival and proliferation while blocking differentiation. ST101 is a C/EBP peptide antagonist having anti-tumor action in glioblastoma (GBM), breast cancer (BC), prostate cancer (PC), melanoma, and other cancer models.Methodologies:In patients…

Meredith McKean, MD, Associate Director, Melanoma and Skin Cancer Research Program at Sarah Cannon Research Institute speaks about ESMO 2021 Abstract – 525P – Efficacy, safety, pharmacokinetic (PK) and pharmacodynamic (PD) data from phase I dose escalation of a novel therapeutic peptide, ST101, targeting the oncogenic transcription factor C/EBPβ, in patients (pts) with advanced and metastatic solid tumors.Link to Abstract:https://oncologypro.esmo.org/meeting-resources/esmo-congress-2021/efficacy-safety-pharmacokinetic-pk-and-pharmacodynamic-pd-data-from-phase-i-dose-escalation-of-a-novel-therapeutic-peptide-st101-targeting 525P Abstract:History:CCAAT/enhancer-binding protein (C/EBP), an oncogenic transcription factor, promotes tumor survival and proliferation while blocking differentiation. ST101 is a C/EBP peptide antagonist having anti-tumor action in glioblastoma (GBM), breast cancer (BC), prostate cancer (PC), melanoma, and other cancer models.Methodologies:In patients…

Amy Moore, Ph.D., VP, Global Engagement and Patient Partnerships at LUNGevity Foundation speaks about LUNGevity Foundation Launches New Lung Cancer Patient Gateways. Link to LUNGevity:https://www.lungevity.org/Link to Article:https://www.lungevity.org/news/media-releases/lungevity-foundation-launches-new-lung-cancer-patient-gatewaysThe LUNGevity Foundation, the country’s foremost lung cancer nonprofit, has launched a new resource called Lung Cancer Patient Gateways. The KRAS Patient Gateway is the first to go live, and it will make it easier for cancer patients with the KRAS gene mutation to obtain resources and treatment information, as well as connect with other patients and caregivers.The KRAS Patient Gateway is a user-friendly and easily available information site that provides persons with KRAS…

Amy Moore, Ph.D., VP, Global Engagement and Patient Partnerships at LUNGevity Foundation speaks about LUNGevity Foundation Launches New Lung Cancer Patient Gateways. Link to LUNGevity:https://www.lungevity.org/Link to Article:https://www.lungevity.org/news/media-releases/lungevity-foundation-launches-new-lung-cancer-patient-gatewaysThe LUNGevity Foundation, the country’s foremost lung cancer nonprofit, has launched a new resource called Lung Cancer Patient Gateways. The KRAS Patient Gateway is the first to go live, and it will make it easier for cancer patients with the KRAS gene mutation to obtain resources and treatment information, as well as connect with other patients and caregivers.The KRAS Patient Gateway is a user-friendly and easily available information site that provides persons with KRAS…

Mansoor Raza Mirza, MD, chief oncologist at Copenhagen University Hospital in Denmark speaks about the FDA Approves Pembrolizumab Plus Chemo as First-Line Therapy for Advanced, Recurrent Cervical Cancer.Link to Article:https://www.medscape.com/viewarticle/960819?src=Pembrolizumab (Keytruda, Merck) and conventional chemotherapy — with or without bevacizumab — have been approved by the US Food and Drug Administration (FDA) as first-line therapy for patients with persistent, recurrent, or metastatic PD-L1-expressing cervical cancer.The first-line approval comes on the heels of the KEYNOTE-826 trial’s phase 3 data, which were reported at the European Society for Medical Oncology (ESMO) Congress 2021 last month.The FDA also announced the regular approval of…

Mansoor Raza Mirza, MD, chief oncologist at Copenhagen University Hospital in Denmark speaks about the FDA Approves Pembrolizumab Plus Chemo as First-Line Therapy for Advanced, Recurrent Cervical Cancer.Link to Article:https://www.medscape.com/viewarticle/960819?src=Pembrolizumab (Keytruda, Merck) and conventional chemotherapy — with or without bevacizumab — have been approved by the US Food and Drug Administration (FDA) as first-line therapy for patients with persistent, recurrent, or metastatic PD-L1-expressing cervical cancer.The first-line approval comes on the heels of the KEYNOTE-826 trial’s phase 3 data, which were reported at the European Society for Medical Oncology (ESMO) Congress 2021 last month.The FDA also announced the regular approval of…

Misako Nagasaka, MD, Ph.D. UCI Health speaks about AnHeart and Innovent Announce Interim Data from Phase â…¡ Trial (TRUST) of Taletrectinib in ROS1-Positive NSCLC at the CSCO 2021 Annual Meeting.Link to Article:https://www.businesswire.com/news/home/20210927005229/en/AnHeart-and-Innovent-Announce-Interim-Data-from-Phase-%E2%85%A1-Trial-TRUST-of-Taletrectinib-in-ROS1-Positive-NSCLC-at-the-CSCO-2021-Annual-MeetingAnHeart Therapeutics Co., Ltd, a clinical-stage biopharmaceutical company focused on developing novel first-in-class or best-in-class precision oncology therapeutics, and Innovent Biologics, Inc., a world-class biopharmaceutical company focused on developing, manufacturing, and commercializing high-quality medicines for the treatment of cancer, metabolic, autoimmune, and other major diseases, announced today interim clinical data from a Phase II trial (TRUST) evaluating t (NSCLC). On September 25-29, 2021, the findings will be presented as…

Misako Nagasaka, MD, Ph.D. UCI Health speaks about AnHeart and Innovent Announce Interim Data from Phase â…¡ Trial (TRUST) of Taletrectinib in ROS1-Positive NSCLC at the CSCO 2021 Annual Meeting.Link to Article:https://www.businesswire.com/news/home/20210927005229/en/AnHeart-and-Innovent-Announce-Interim-Data-from-Phase-%E2%85%A1-Trial-TRUST-of-Taletrectinib-in-ROS1-Positive-NSCLC-at-the-CSCO-2021-Annual-MeetingAnHeart Therapeutics Co., Ltd, a clinical-stage biopharmaceutical company focused on developing novel first-in-class or best-in-class precision oncology therapeutics, and Innovent Biologics, Inc., a world-class biopharmaceutical company focused on developing, manufacturing, and commercializing high-quality medicines for the treatment of cancer, metabolic, autoimmune, and other major diseases, announced today interim clinical data from a Phase II trial (TRUST) evaluating t (NSCLC). On September 25-29, 2021, the findings will be presented as…